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Highlights 
What is already known about this topic? 
 Population-wide screening for melanoma is unlikely to be cost-effective, but the cost-effectiveness of 
targeted surveillance in high-risk groups is unknown. 
What this study adds 
 A self-completed risk assessment tool yielding a summary score may be a viable approach to identifying 
high-risk groups. 
 The decision model presented here synthesises all relevant, current evidence on the costs and 
consequences of various targeted surveillance strategies. 
 In a UK setting, we estimate that those identified as ‘moderate’ risk should be offered a one-off full-
body skin examination.  Those at increasing risk should be enrolled into quinquennial monitoring, rising 
to annual monitoring for the highest risk.  This strategy would cost £10,199 per QALY gained, but full 
uptake could cost £164m per year, and there is substantial uncertainty associated with the decision. 
What insights does the paper provide? 
 Risk-stratified surveillance is on average cost-effective but expensive.   
 However, there is substantial decision uncertainty. 
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Abstract 
Background: Population-wide screening for melanoma is unlikely to be cost-effective.  However, targeted 
surveillance of high risk individuals may be. 
Objective: To estimate the cost-effectiveness of various surveillance strategies in the UK population, stratified 
by risk using a simple self-assessment tool scoring between 0-67 (Williams et al. 2011). 
Methods: Decision model comparing alternative surveillance policies from the perspective of the UK NHS over 
30 years.  The strategy with the highest expected net benefit for each risk score is identified, resulting in a 
compound risk-stratified policy describing the most cost-effective population-wide strategy.  The overall 
expected cost and QALYs, the incremental cost-effectiveness ratio and associated uncertainty are reported. 
Results: The most cost-effective strategy is for those with a Williams score of 15-21 (relative risk of 0.79 to 1.60 
versus a mean score in the UK of 17) to be offered a one-off full-body skin examination, and for those with a 
score of 22 or more (RR 1.79+) to be enrolled into a quinquennial monitoring programme, rising to annual recall 
for those with a risk score above 43 (RR 20.95+).  Expected incremental cost would be £164m per annum (~0.1% 
of NHS budget), gaining 15,947 additional QALYs, yielding an ICER of £10,199 per QALY gained (51.3% probability 
<£30,000). 
Conclusions: The risk-stratified policy would be expensive to implement but cost-effective compared to typical 
UK thresholds (£20,000 - £30,000 per QALY gained), although decision uncertainty is high.  Phased 
implementation, enrolling only higher risk individuals would be substantially less expensive, but with consequent 
foregone health gain. 
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Introduction 
Approximately 14,500 new cases of malignant melanoma are diagnosed and approximately 2600 deaths occur 
in the UK each year.1  Early detection is critical: 90% of patients survive for five or more years, but this falls to 
25% of women and less than 10% of men with metastatic disease at diagnosis.1  The cost of treating metastatic 
melanoma far outweighs the cost of treating primary melanoma and the relative increase has risen sharply with 
the recent introduction of several high cost drugs that palliate for the most part.  For example, nivolumab costs 
approximately £70,000 per patient per year for an additional gain of 1.3 QALYs compared with dacarbazine.2  
Screening programmes are therefore of increasing relevance.  The UK National Screening Committee has not 
formally reviewed whether a programme for melanoma would be an efficient use of public funds.3  However, 
existing evidence suggests such a programme would have difficulty identifying the target population,4 raises 
concerns about whether a comprehensive programme could be cost-effective5 and cites lack of evidence on the 
cost-effectiveness of full-body skin examination (FBSE), except in those with a history of melanoma.6 
Two recent systematic reviews7 8 concluded that whilst skin cancer prevention initiatives are highly cost-
effective,7 there is a lack of evidence on the cost-effectiveness of early detection programmes,7 and future 
research should focus on targeted screening/surveillance in high risk populations.8  Based on this, the US 
Preventive Services Task Force (2016) reiterated its previous recommendation9 that the “current evidence is 
insufficient to assess the balance of benefits and harms of visual skin examination… to screen for skin cancer in 
adults.”10 
Several tools have been developed to enable identification of higher risk individuals.11 One of the better 
performing was developed from a case-control study in the USA by Williams et al.12 It is a self-assessed clinical 
risk estimation model not requiring expert FBSE that, in a split-sample validation population, had an area under 
the receiver operator characteristic curve of 0.70 (95%C.I. 0.64 to 0.77) and was able to identify 15% of the 
population in whom 50% of melanomas would be expected to develop.12 We have recently shown that it is both 
feasible and acceptable to collect data on risk of melanoma in the waiting rooms of UK family practices and that 
using the Williams model produces a distribution of risk in the attending population which allows identification 
of sub-groups at different levels of risk.13  
The purpose of this study is to establish whether using the Williams model and resulting score to risk-stratify the 
population and guide future management is a cost-effective approach to reducing mortality and morbidity from 
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melanoma in a UK setting.  Key to this is determining the risk score at which it is most cost-effective to enrol 
patients into a surveillance programme.  If the score is set too low, primary care capacity will be absorbed 
examining patients with an extremely low risk of melanoma at the expense of other patients with a greater 
capacity to benefit.  If set too high, then patients will be falsely reassured and any benefits in terms of reduced 
melanoma morbidity and mortality will be foregone.  Specifically therefore, this study aims to identify the 
optimal cut-off scores from the Williams self-assessment tool12 at which users are recommended to either (a) 
visit their primary care practitioner for a one-off FBSE, or (b) be entered into a routine primary care-based 
monitoring programme, and if so, (c) the optimal frequency of visits, ranging from 5-yearly to annual. 
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Method 
We substantially adapted and modified a decision model we previously developed for a novel diagnostic aid for 
melanoma.14  The adapted model is a patient level simulation following a simulated cohort of participants (UK 
general public) one by one.  Uncertainty is propagated through the model via Monte Carlo simulation 
(distributions of parameters are specified in Table 1).  The code was written in R,15-17 and run on the University 
of Cambridge High Power Cluster computing facility.  Code is available on request from the corresponding 
author.  Ethical approval was not required for this study. 
The Williams Self-Assessment Tool 
The scenarios we model focus on the Williams self-assessment tool (Appendix 1).12  This is a rapid questionnaire 
comprising eight questions on sex, age, hair colour, density of freckles, history of severe sunburn in childhood 
and adolescence, number of raised moles on the arms and history of non-melanoma skin cancer yielding a 
summary score between 0 (lowest risk) and 67.   
Model definition 
The model comprises two modules: natural history and clinical (Figure 1).  The link between the two is 
determined by the comparator policies, described below.  Cohorts of a given age, gender and Williams score12 
are simulated.  In year zero, the distribution of prevalent melanomas and their disease stages in each cohort is 
estimated based on UK prevalence data and stage at diagnosis,18 19 adjusted for risk score.  The natural history 
module is a Markov-like model and simulates patients’ trajectories over a period of 30 years: each year patients 
are at risk of new melanomas developing according to UK incidence by age and gender19 adjusted for risk score,12 
and undiagnosed (and hence untreated) melanomas progress according to estimated rates of progression.20  
When the model determines that contact is made with the health service, the simulated patient ‘breaks out’ of 
the natural history module  into the clinical module, which has a decision tree structure.  Once reaching a 
terminal node of the decision tree, the patient is returned to the natural history module. 
Natural History Module 
Cutaneous melanoma is categorised into four main types (superficial spreading, lentigo maligna, acral 
lentiginous and nodular)21 each with nine stages of invasion (Stages 1a to 4) plus an in situ stage for all except 
nodular melanoma (which is by definition invasive).22  We assumed that invasive disease would progress at the 
same rate irrespective of primary melanoma subtype, but allowed the rate of progression from in situ disease 
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to vary by subtype, yielding a total of 12 discrete stages describing the disease.  The model also included no 
melanoma and dead health states.  The overall prevalence of undiagnosed melanoma in the community in year 
0 was estimated at 0.162%, assumed the same as that observed in a population screening study in Northern 
Germany18 (Review details Appendix 2).  This was distributed according to risk score by combining with UK 
relevant epidemiological data.12 19 23 24  The parameters of the resulting risk function are in Table 1.  The annual 
incidence was estimated using an analogous approach.  Full details are in Appendix 3. 
Data on the rate of progression of untreated melanoma do not exist and it would be most unethical to conduct 
a prospective cohort study to establish this empirically.  Therefore data were elicited from a representative 
group of experts in melanoma,20 (Table 1 and Appendix 4).  Age and gender specific background and melanoma-
specific mortality data are extracted from UK lifetables25 (Appendix 5) adjusted for the odds ratio22 (Appendix 
6). 
Clinical Module 
The clinical module describes the patient pathway following health service contact (Figure 1).  The model allows 
two ways for a patient to present in primary care: of their own initiative with a mole that they are concerned 
about, or because they have been advised to do so following a risk assessment.  Any suspicious moles are 
inspected during a FBSE from a primary care practitioner, and the patient either referred to secondary care or 
discharged.  Figure 1 (right hand side) illustrates the pathway; the natural history component of the model will 
have determined whether a patient is healthy (‘D-’) or has melanoma (‘D+’).  For a patient with a melanoma 
(‘D+’), the probability of the primary care practitioner identifying it and referring a patient to secondary care is 
the sensitivity of the practitioner, denoted P(T+|D+), and is based on data from the control arm of a recently 
study of a diagnostic aid in primary care.26  Likewise the probability of correctly discharging a patient without 
melanoma is the specificity (denoted (P(T-|D-) in Figure 1), extracted from the same source.  Data are 
summarised in Table 1. 
Patients with melanoma correctly referred (true positives, with probability P(T+|D+)) receive appropriate 
treatment according to disease stage (‘D&Tstage’ in Figure 1; see section ‘costs’ below for details).  They are then 
flagged as having a history of melanoma and are at risk of mortality as described in the natural history module 
(data based on stage-specific prognosis post diagnosis22).  Patients with melanoma who are not referred (false 
negatives, with probability 1 - P(T+|D+)) are discharged and return to the ‘natural history’ module where they 
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are at risk of disease progression and mortality.  Patients without melanoma (D-) who are referred incur the cost 
of referral followed by discharge to the community.  Finally, patients without melanoma who are not referred 
are reassured and discharged back to the community direct from primary care. 
Contact with health service: comparator policies 
There are seven alternative policies. 
The first is the status quo.  This assumes an ad hoc presentation by a member of the public concerned about a 
skin lesion, the probability of which is estimated at 0.73% per annum19 24 26-28  (Appendix 7).  The second policy 
is to invite all at-risk persons to primary care for a one-off FBSE by a primary care practitioner in year 0; patients 
then present opportunistically (with lesions of concern) in the remaining years.  Policies 3-7 represent enrolment 
into a primary care-based monitoring programme with increasing frequency of recall from five-yearly to annual.  
Thus, under policy 3 patients attend for a body examination in years 0, 5, 10, 15…, (with ad hoc presentation in 
the intervening years).  Under policy 4, patients present in years 0, 4, 8, 12, and so forth.   
In policies 2-7, we assume the Williams tool is used by members of the public to assess their own risk prior to 
contact with the health service.  This could be administered, for example, via a leaflet in pharmacies, primary 
care waiting rooms or other public places, or electronically via a smartphone app.  The objective of this analysis 
is to determine the optimal cut-off scores at which each of the seven policies is recommended.   
Costs 
The perspective and price year of the analysis is the UK NHS and 2015, with future costs discounted at a rate of 
3.5%.  Unit costs were extracted from standard NHS sources,29 30 and care pathways and primary care 
consultation time from current guidelines31 and a recent clinical trial26  (Table 1 and Appendix 8).   
Health state Utilities 
A systematic review of health related quality of life in patients with melanoma identified three distinct periods 
of impact of the disease: at diagnosis, treatment and follow-up.32  We assumed that patients who are unaware 
they have melanoma suffer no impairment in quality of life (assigned a utility of 1), whilst from the point of 
diagnosis, a health utility impairment was assigned as per the authors’ previous model in a related area,14 
adapted from a study of health related quality of life measurement in melanoma patients33  (Table 1).  
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Model Calculation and analysis 
To determine the appropriate cohort size and number of iterations, one of the seven scenarios under one 
age/gender/risk score (baseline scenario, 35yo male, risk score 17) was run under a range of cohort sizes and 
iterations a total of 50 times.  The coefficient of variation (CV) of the expected and standard errors of cost and 
QALYs were calculated from these, with a ‘target’ CV of 2% or below considered ‘stable’.  A cohort size of 1000 
and 1000 iterations yielded coefficients of variation of 0.39%, 2.21%, 0.01% and 1.93% for mean cost, SE mean 
cost, mean QALYs and SE mean QALYs respectively  (Appendix 9). 
The model therefore generates 1,000 patients of a given age, gender and risk score group, and simulates their 
development, progression and treatment of melanoma over 30 years under each of the seven policies 1000 
times.  We estimated the expected cost, QALYs and net benefit (defined as the QALY gain multiplied by the 
thresholds of £20,000 and £30,000, less the cost) for each policy.  The model was calculated for each of the 
seven policies at seven selected values for the Williams risk score (10, 17, 20, 25, 30, 50 and 60), males and 
females, and four starting ages (35, 45, 55 and 65).  Results were weighted for the age/gender of the UK 
population to yield costs, outcomes and net benefit by risk score alone.  The risk scores at which the model was 
evaluated were chosen to get a spread of scores, but included 17 as this is the mean risk score for the UK 
population.13  Net benefits for intervening scores were estimated by linear interpolation.   
The policy yielding the highest net benefit was noted for each risk score, and the cut-off scores at which the 
optimal policy changed identified.  This risk-stratified policy describes the most cost-effective strategy given the 
epidemiology and demographics of the UK population.  The overall expected cost and QALY gains of this risk-
stratified policy are applied to the UK population, and compared with expected cost and QALYs of the status 
quo, thus estimating the overall incremental cost per QALY gained of the stratified policy versus status quo. 
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Results 
Figures 2a&b show the expected net benefit and 95% credibility intervals from each policy as a function of 
selected risk scores at a willingness to pay (WTP) of £20,000 and £30,000 per QALY respectively (data in Appendix 
10, additional figures Appendix 11).  At lower risk scores, all options have a very similar expected net benefit.  
As the risk score increases, the expected net benefit of status quo (no screening) and the less intensive policies 
drops below that of the more intensive policies.   
Given a WTP of £30,000 per QALY the optimal policy is for those with a risk score between 15 and 21 to be 
offered a one-off FBSE to check for melanoma.  Those with a risk score of 22 and above should be enrolled into 
a monitoring programme with quinquennial recall, rising to annual for those with a score over 43.   
If this ‘compound’ policy were to be enacted across the UK, the expected additional cost per person over 30 
years would be £164.89, yielding an extra 0.016 QALYs per person.  The incremental cost per QALY gained is thus 
£10,199.  (Table 2; Appendix 10).  The 95% credibility ellipse (Figure 3) and cost-effectiveness acceptability curve 
(Figure 4) illustrate the high decision uncertainty; at NICE’s threshold of around £20,000 to £30,000, there is only 
a 51.0% to 51.3% probability that the policy is cost-effective.  Thus, whilst the compound risk-adjusted policy 
yielding the highest expected net benefit can be identified (Table 2), there is a great deal of decision uncertainty.  
This is a function of both the small absolute difference in net benefit between policies at lower risk scores (Figure 
2), and the substantial parameter uncertainty (Table 1).  The probability of cost-effectiveness does not exceed 
51-52% due to the proportion of the probability mass in the north-west quadrant of the cost-effectiveness plane, 
representing scenarios where the policy is both more expensive but less effective (i.e. yields fewer QALYs) than 
the status quo (Figure 3). 
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Discussion 
Interpretation of results 
The results in Table 2 and Figure 2 show how the recommended intensity of surveillance increases with risk 
score, from status quo (no screening programme), rising to enrolment in a monitoring programme of increasing 
frequency of recall for the highest risk individuals.  This suggests the model has face validity.  However, we are 
also able to identify the most efficient cut-off scores for these recommendations: all those with a Williams’ risk 
score greater than 15 should have a one-off FBSE with a primary care practitioner.  Those with a risk score 
greater than 22 should be enrolled into a primary care-based monitoring programme with 5-year recall, rising 
to annual monitoring for those with a score above 43. 
The mean risk score in the UK population is 17.13  Implementing this policy in the UK would involve inviting an 
estimated 61% of the adult population to at least one examination (approximately 29.9m people), at an extra 
cost of £4.9bn over 30 years, or approximately £164m per year (0.1% of the 2016 NHS budget).  This cost is the 
present value discounted at 3.5% per annum and includes the cost of monitoring as well as subsequent referrals 
and surgery.  However, this would yield approximately 15,947 additional QALYs per year: an incremental cost 
per QALY of £10,199, well within what is usually considered cost-effective in the UK (£20,000 to £30,000 per 
QALY).34  By way of comparison the existing breast screening programme in the UK adds approximately £42.5m 
to NHS expenditure, but generates around 2,040 extra QALYs (£20,800 per QALY gained).35  A phased 
implementation involving only higher risk individuals would be substantially less expensive, but with consequent 
foregone health gain. 
These recommendations are based on expected values, rather than on the results of hypothesis tests.  This 
approach is consistent with statistical decision theory,36 a key assumption of which is that decision makers are 
risk neutral37 and thus interested in maximising expected outcomes subject to budgetary constraints.  
Uncertainty in decisions therefore should not be a factor in whether to adopt one particular strategy or another, 
but is critical to guide future research, ideally via value of information analysis.38 39  Our analysis suggests that 
there is a great deal of decision uncertainty, with only a 51%-52% probability that such a surveillance programme 
is cost-effective (Figure 3).40  A phased implementation as suggested above must provide the opportunity to 
reduce decision uncertainty, for example through a cluster or stepped-wedge randomised controlled trial.  This 
would inform the decision to either expand the scheme to lower risk individuals, limit to higher risk, or disinvest 
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entirely.  Additional preparatory research to establish the feasibility, sensitivity and specificity of nurses in 
conducting a FBSE as part of a screening programme is also critical. 
Strengths & Weaknesses 
As with any decision model, the robustness of the policy recommendations is contingent on the quality of the 
modelling and availability of source data.  Our model is a patient level simulation of a complex decision 
framework with a total of 476 possible compound policies (seven strategies at 68 risk scores).  The model 
development process was methodical and rigorous, gathering the most appropriate evidence on all input 
parameters. 
The major limitations in the model were due to lack of relevant data.  Specifically, the risk of progression in 
undiagnosed melanoma was based on expert opinion.20 This limitation is common to many decision analyses, 
particularly of screening studies: in order to quantify the added health benefit of screening, it is necessary to 
know the disease course of those who would otherwise not be identified and treated.  Prospectively withholding 
treatment from melanoma patients to observe this would clearly be deeply unethical therefore the only 
alternative is to seek expert opinion.  A number of techniques exist (e.g.41), a key feature of which is that they 
focus on eliciting experts’ uncertainty (in terms of a range of plausible values, weighted according to strength of 
belief) rather than a single ‘best guess’ for a particular parameter.  We conducted an elicitation exercise in a 
transparent and replicable manner to address this issue.20 Due to a lack of evidence,10 we were also unable to 
include potential screening-related harms in the model. These include risk of overdiagnosis,42 side effects of 
treatment, or psychological harms43 and are important when considering any future screening programme. 
Treatment of late stage disease in the model is based on 2010 guidelines which do not include newer, expensive 
treatments of varying cost-effectiveness.44-46  If these add substantial cost with limited health gain, it becomes 
even more cost-effective to detect (and thus treat) earlier in the disease process.  
Further limitations include the costs and practicalities of introducing such surveillance.  We assumed all patients 
initially receive a FBSE by a GP.  Not offering a full body examination may reduce the cost of the consultation, 
but at risk of lower sensitivity.  A community nurse conducting the examinations would be less expensive than 
a GP, but since the current gold standard is examination in secondary care, costs of providing and training for 
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both GP and nurse would need consideration.47 Surveillance could be offered in other locations such as 
community clinics and via telemedicine.48 
We assumed perfect adherence and did not explicitly account for recurrent or multiple lesions.  Lower adherence 
will reduce both costs and health gain from the programme.  Recurrent skin cancers were indirectly accounted 
for in the post-treatment survival functions.22  Patients with multiple lesions will have increased surgical costs, 
but the marginal cost is likely to be small compared with the cost of non-surgical treatment at later stages of the 
disease and so is unlikely to alter our conclusions substantially. 
The baseline utility for patients was assumed equal to perfect health (i.e. 1).  Population norms suggest a 
declining utility with age.49 However, the model applies an absolute reduction in utility (and hence QALYs) with 
various health states, thus the incremental QALY gain is insensitive to this. 
A final limitation was that we only considered a maximum recall interval of 5 years.  It may be more efficient for 
recall to be less frequent for medium risk individuals, for example, decennially.  However, this was out of scope 
of this analysis. 
Despite these caveats, the model is based on the best evidence available to the authors at the time of writing: 
no decision model is perfect and can always be improved.  Decisions as to what concepts to include in a decision 
model must be balanced against the resources available to conduct it, and the need for a timely policy 
recommendation.  Acknowledged limitations of a decision model, both in terms of structure and data inputs, 
provide an agenda for future research in the area. 
Conclusion 
Current evidence is highly uncertain but suggests that, on balance, a UK-wide programme to identify patients at 
risk of melanoma using the Williams self-assessment tool is potentially cost-effective.  Nevertheless, a 
programme would be expensive to implement due to its scale.  Additional research into the feasibility, sensitivity 
and specificity of nurses in conducting FBSE as part of a programme is required.  Ultimately a phased 
implementation, targeting only the highest risk groups may be practical to implement, but must be embedded 
within a rigorous randomised trial to reduce decision uncertainty and hence inform further rollout. 
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Table 1: Input parameters 
Parameter Dbn Hyperparameters mean median SE 95% CrI  
Probability of prevalent melanoma in year 0 by risk score* 
𝛼 N (-8.454, 0.119) -8.454  0.119   
𝛽 N (0.100, 0.008) 0.100  0.008   
Annual probability of incident melanoma by risk score* 
𝛼 N (-10.270, 0.186) -10.270  0.186   
𝛽 N (0.117, 0.008) 0.117  0.008   
Transition Probabilities (From state > To state)**  
ISLM>ISLM mCM 
(
  
 
0.167 0.102 0.023 0.999
9.624 2.133 0.073 0.956
9.885 9.988 0.039 0.604
2.412 9.960 0.101 0.994
9.964 3.223 0.019 0.665
9.810 9.970 0.649 0.964)
  
 
 
 0.92  (0.02, 1.00) 
20 
ISLM>1A   0.06  (0.00, 0.88)  
ISLM>1B   0.00  (0.00, 0.11)  
ISLM>2A   0.00  (0.00, 0.07)  
ISLM>2B   0.00  (0.00, 0.09)  
ISLM>2C   0.00  (0.00, 0.07)  
ISLM>3A   0.00  (0.00, 0.02)  
ISSS>ISSS mCM 
(
  
 
0.739 0.319 0.003 0.996
2.069 2.033 0.610 1.000
9.055 6.031 0.012 0.973
9.687 2.788 0.034 0.903
7.133 9.546 0.264 0.990
0.450 0.137 0.038 0.621)
  
 
 
 0.83  (0.03, 1.00)  
ISSS>1A   0.14  (0.00, 0.82)  
ISSS>1B   0.02  (0.00, 0.15)  
ISSS>2A   0.01  (0.00, 0.08)  
ISSS>2B   0.00  (0.00, 0.02)  
ISSS>2C   0.00  (0.00, 0.01)  
ISSS>3A   0.00  (0.00, 0.01)  
ISAL>ISAL mCM 
(
 
 
 
 
0.839 0.386 0.000 0.999
1.492 0.248 0.000 0.759
10.000 10.000 0.000 0.969
6.603 8.078 0.000 0.777
8.718 9.295 0.000 0.671
9.634 10.000 0.247 0.810
8.705 9.196 0.000 0.973)
 
 
 
 
 
 0.79  (0.03, 1.00)  
ISAL>1A   0.13  (0.00, 0.70)  
ISAL>1B   0.03  (0.00, 0.23)  
ISAL>2A   0.01  (0.00, 0.09)  
ISAL>2B   0.01  (0.00, 0.05)  
ISAL>2C   0.01  (0.00, 0.06)  
ISAL>3A   0.00  (0.00, 0.02)  
ISAL>3B   0.00  (0.00, 0.00)  
1A>1A mCM 
(
 
 
 
 
 
 
1.034 0.568 0.000 0.999
9.734 9.973 0.004 1.000
2.932 9.951 0.002 1.000
0.052 0.233 0.009 0.985
9.865 9.992 0.000 0.365
0.011 0.126 0.031 0.989
9.867 9.903 0.021 0.993
0.000 9.995 0.014 0.962
0.000 9.971 0.009 0.999)
 
 
 
 
 
 
 
 
 0.72  (0.05, 1.00)  
1A>1B   0.14  (0.00, 0.53)  
1A>2A   0.03  (0.00, 0.16)  
1A>2B   0.00  (0.00, 0.26)  
1A>3A   0.01  (0.00, 0.08)  
1A>2C   0.00  (0.00, 0.10)  
1A>3B   0.02  (0.00, 0.17)  
1A>3C   0.00  (0.00, 0.00)  
1A>4   0.00  (0.00, 0.00)  
1A>ISSS   0.02  (0.00, 0.16)  
1B>1B mCM  0.69  (0.10, 0.92)  
1B>2A   0.14  (0.03, 0.52)  
1B>2B   0.03  (0.00, 0.33)  
1B>2C   0.03  (0.00, 0.18)  
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1B>3A  
(
 
 
 
 
 
0.448 0.294 0.098 0.924
10.000 9.915 0.000 0.957
0.893 1.659 0.000 0.963
0.000 9.696 0.393 0.910
0.232 0.398 0.000 0.939
9.841 9.398 0.000 0.934
9.526 9.769 0.065 0.968
9.809 0.845 0.081 0.931)
 
 
 
 
 
 
 
 0.01  (0.00, 0.18)  
1B>3B   0.01  (0.00, 0.12)  
1B>3C   0.01  (0.00, 0.07)  
1B>4   0.01  (0.00, 0.06)  
1B>1A   0.00 
 
(0.00, 0.00) 
 
2A>2A mCM 
(
  
 
1.688 1.004 0.000 0.918
2.725 2.357 0.023 0.962
8.995 9.106 0.000 0.629
0.524 0.623 0.220 0.884
5.262 8.588 0.266 0.691
0.078 1.900 0.470 0.818)
  
 
 
 0.61  (0.11, 0.91)  
2A>2B   0.18  (0.03, 0.60)  
2A>3A   0.05  (0.01, 0.19)  
2A>2C   0.05  (0.01, 0.25)  
2A>3B   0.02  (0.00, 0.10)  
2A>4   0.01  (0.00, 0.07)  
2A>3C   0.01  (0.00, 0.05)  
2B>2B mCM 
(
  
 
0.260 0.257 0.009 0.994
4.960 10.000 0.008 0.987
2.069 2.495 0.028 0.977
4.565 5.173 0.019 0.991
0.140 0.230 0.010 0.991
0.387 0.262 0.010 0.984)
  
 
 
 0.52  (0.01, 0.99)  
2B>2C   0.14  (0.00, 0.49)  
2B>3A   0.11  (0.00, 0.52)  
2B>3B   0.06  (0.00, 0.31)  
2B>3C   0.00  (0.00, 0.24)  
2B>4   0.00  (0.00, 0.21)  
2B>2A   0.00  (0.00, 0.11)  
2C>2C mCM 
(
 
 
1.977 2.396 0.014 0.954
0.129 0.174 0.058 0.986
1.036 1.319 0.000 0.943
1.813 1.456 0.030 0.932
4.446 1.759 0.061 0.927)
 
 
 
 0.44  (0.09, 0.83)  
2C>3A   0.14  (0.01, 0.82)  
2C>3B   0.07  (0.00, 0.52)  
2C>3C   0.05  (0.00, 0.41)  
2C>4   0.03  (0.00, 0.26)  
2C>2B   0.00  (0.00, 0.04)  
3A>3A mCM 
(
 
 
 
 
 
1.393 0.993 0.013 0.977
1.360 1.643 0.015 0.987
0.983 0.587 0.011 1.000
1.691 0.340 0.012 0.991
0.437 0.072 0.027 0.993
0.035 0.218 0.022 0.993
4.673 0.697 0.021 0.969
0.033 0.327 0.007 0.990)
 
 
 
 
 
 
 0.61  (0.08, 0.96)  
3A>3B   0.15  (0.01, 0.63)  
3A>3C   0.09  (0.00, 0.54)  
3A>4   0.03  (0.00, 0.35)  
3A>1A   0.00  (0.00, 0.00)  
3A>1B   0.00  (0.00, 0.01)  
3A>2A   0.00  (0.00, 0.00)  
3A>2B   0.00  (0.00, 0.00)  
3A>2C   0.00  (0.00, 0.00)  
3B>3B mCM (
1.253 2.103 0.126 0.995
2.722 1.932 0.003 0.997
)  0.43  (0.15, 0.87)  
3B>3C   0.30  (0.05, 0.68)  
3B>4   0.14  (0.02, 0.44)  
3C>3C mCM (3.785 2.926 0.008 0.988)  0.57  (0.21, 0.87)  
3C>4    0.31  (0.08, 0.66)  
Odds ratio of death by disease stage (vs 1A)***  
1A - - 1  0  
22 
1B LN (1.449, 0.007) 4.261  0.007   
2A LN (2.506, 0.007) 12.250  0.007   
2B LN (3.045, 0.007) 21.000  0.007   
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2C LN (3.731, 0.008) 41.741  0.008   
3A LN (2.626, 0.010) 13.821  0.010   
3B LN (3.486, 0.008) 32.667  0.008   
3C LN (4.215, 0.011) 67.667  0.011   
4 LN (5.743, 0.006) 312.104  0.006   
Sensitivity and Specificity of primary care practitioner at detecting melanoma 
Sensitivity 
(P(T+|D+)) β (29, 7) 80.1%   
(66.3%, 
91.6%) 
26 
Specificity 
(P(T-|D-)) β (864, 536) 61.7%   
(59.2%, 
64.2%) 
26 
Costs 
GP 
consultation 
(per minute) 
 Constant £3.80  
  
29 
GP 
consultation 
time (minutes) 
N (22.1,3.2) 22.1  
  
26 
Initial referral Γ (20.408, 5.439) £111    
30 
Biopsy 
excision 
Γ (10.443, 13.694) £143  
  
30 
Definitive 
surgery 
Γ (3.762, 41.468) £156  
  
30 
CXR Γ (12.430, 2.414) £30    
30 
CT Scan Γ (13.616, 9.695) £132    
30 
Liver function 
test 
Γ (4.041, 0.742) £3  
  
30 
FBC Γ (4.041, 0.742) £3    
30 
Sentinel node 
biopsy 
Γ (1.165, 24.887) £29  
  
30 
Radical lymph 
node 
dissection 
Γ (1.808, 547.925) £991  
  
30 
Surgical 
removal of 
localised 
metastases 
Γ (1.256, 577.101) £725  
  
30 
Radiotherapy 
(planning) 
Γ (8.890, 82.673) £735  
  
30 
Radiotherapy 
(per fraction) 
Γ (17.014, 7.758) £132  
  
30 
Chemotherapy 
(dacarbazine, 
procurement) 
Γ (1.330, 209.827) £279  
  
30 
Chemotherapy 
(dacarbazine, 
delivery first 
attendance) 
Γ (6.934, 26.823) £186  
  
30 
Chemotherapy 
(dacarbazine, 
delivery 
subsequent) 
Γ (3.239, 62.988) £204  
  
30 
Dermatology 
follow-up 
Γ (12.183, 7.962) £97  
  
30 
Summary Costs      
GP consultation £83.98     
Chemotherapy, cycle £1485     
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Radiotherapy, 10 fraction cycle £2055     
By disease stage      
D&T In situ (SS, LM, AL) £396     
D&T stage 1a, 1b £1463     
D&T stage 2a £1880     
D&T stage 2b, 2c £2048     
D&T stage 3a, 3b, 3c £3171     
D&T stage 4 £4761     
Final year of life in situ, 1a (i.e. states ‘dead IS’, ‘dead 1a’) £0     
Final year of life stage 1b-4 £4265     
Health State Utilities 
No melanoma C - 1.00  - -  
Undetected 
disease 
C - 1.00 
 - - 
 
Detected & treated, and post D&T: 
Stage 0  N (0.93, 0.013) 0.93    
33 
Stage 1  N (0.93, 0.013) 0.93    
33 
Stage 2  N (0.87, 0.057) 0.87    
33 
Stage 3  N (0.89, 0.046) 0.89    
33 
Stage 4  N (0.52, 0.117) 0.52    **** 
Last year of 
life with IS or 
1a disease 
(states ‘dead 0’ 
and ‘dead 1a’ 
N (0.93, 0.013) 0.93 
   
33 
Last year of 
life with Stage 
1b – 4 disease 
N (0.52, 0.117) 0.52 
   
33 
Dead C - 0     
So: Source.  
* 𝑃(𝑝𝑟𝑒𝑣𝑎𝑙𝑒𝑛𝑡 𝑜𝑟 𝑖𝑛𝑐𝑖𝑑𝑒𝑛𝑡 𝑚𝑒𝑙𝑎𝑛𝑜𝑚𝑎 𝑖𝑛 𝑦𝑒𝑎𝑟 𝑧𝑒𝑟𝑜) =  𝑒(𝛼+𝛽𝑊),where W is risk score.  mCM:  modified 
Connor-Mosimann distribution.  Parameters are presented as a (k-1)*4 matrix.  Parameters relate to six-month 
transition probabilities (elicited probabilities were over a 6 not 12-month time horizon), which form the inputs to 
the modified Connor-Mosimann distribution.  Columns mean, median, 95%CrI represent the respective moments 
of the twelve-month transition marginal probability distribution.  Please see Appendix 4 for further details.  ISLM: 
In situ lentigo maligna melanoma; ISSS: In situ superficial spreading melanoma; ISAL: in situ acral lentiginous 
melanoma; 1A, 1B etc: invasive melanoma of stage 1A, 1B etc. SE: Standard Error. CrI: Credibility Interval. LN: 
Log Normal. N: Normal. C: Constant.  Dbn: Distribution. D&T: Diagnosed and Treated. GP: General 
Practitioner.  CXR: Chest X-ray.  FBC: Full Blood Count.  
**Note medians are aggregated from individual summaries so do not total 100% 
***Parameters of log-normal distribution are the natural log of the mean and the standard error of the natural 
log of the mean. C= Constant.  
**** Assumption based on reference 33
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Table 2: Recommendations by risk score. 
    Status Quo Monitoring programme 
Risk 
score 
 
Equiv. RR Optimal policy 
% of 
popn £ (SE) QALYs (SE) 
Cov(£,
Q) £ (SE) QALYs (SE) Cov(£,Q) 
0-14 0.14 – 0.70 Do nothing 38.6% £34.99 (£6.79) 28.388 (0.346) -0.449 £34.99 (£6.79) 28.388 (0.346) -0.449 
15-21 0.79 – 1.60 One-off exam 33.9% £24.99 (£7.47) 16.347 (0.107) -0.113 £141.3 (£18.01) 16.352 (0.107) -0.072 
22-28 1.79 – 3.62 5-yearly monitoring 19.4% £40.87 (£15.48) 16.705 (0.094) -0.476 £402.09 (£49.34) 16.727 (0.09) -0.100 
29-32 4.07 – 5.78 3-yearly monitoring 4.6% £57.61 (£27.27) 14.638 (0.103) -3.135 £573.01 (£75.42) 14.684 (0.086) -0.567 
33-42 6.50 – 18.63 2-yearly monitoring 3.2% £219.62 (£109.45) 19.354 (0.256) -40.098 £1128.51 (£129.7) 19.592 (0.121) -4.259 
43+ 20.95+ Annual monitoring 0.2% £170.45 (£123.05) 8.909 (0.263) -35.990 £1105.36 (£176.67) 9.124 (0.085) 1.184 
  Weighted average £40.05 (£23.22) 21.066 (0.234) -1.824 £204.93 (£38.47) 21.082 (0.229) -0.377 
  ICER     £10,198.57   
‘Status Quo’ costs and QALYs represent the current expected costs and QALYs accrued by members of the 
population with various risk scores over a period of 30 years (figures discounted at 3.5%pa).  ‘Monitoring 
programme’ shows the expected cost and QALYs accrued by those same patients under the ‘optimal policy’ 
option.  Thus there is no change in cost or outcomes for those with a risk score under 14.  The extra cost for those 
with a score of 15-21 represents the expected cost of the one-off exam and subsequent referral and treatment 
where incurred.  The added benefit in these patients is 0.005 QALYs.  
RR- relative risk of incident melanoma vs mean risk score in UK of 1713 (calculations based on ratio of expected 
incidences at respective risk scores as per equation described in Appendix 2); Popn- population; £ - GB Pound; 
SE – Standard Error; Cov- Covariance; Q- QALYs; ICER- Incremental Cost Effectiveness Ratio. 
 
 
1. Usher-Smith JA, Kassianos AP, Emery JD, et al. Identifying people at higher risk of melanoma 
across the U.K.: a primary-care-based electronic survey. Br J Dermatol 2017;176(4):939-48 
doi: 10.1111/bjd.15181. 
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Figure 1: Model schematic 
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D+/D-: patient with or without melanoma.  P(T+|D+): probability of a positive diagnosis given the patient has melanoma (sensitivity).  P(T-|D-): probability of a 
negative diagnosis given the patient does not have melanoma (specificity).  D&Tstage: diagnosis and treatment in secondary care according to disease stage. Hxstage: 
Patient with history of treated disease of a given stage. 
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Figure 2a: Expected net benefit +/- 95% credibility interval, threshold = £20,000 per QALY. 
 
Figure 2b: Expected net benefit +/- 95% credibility interval, threshold = £30,000 per QALY 
 
Policies are ranked in order of intensity: 0=status quo, 1=One-off exam, 2-6: enrolment in monitoring programme 
with examination every 5-1 years respectively.  Expected net benefit and 95% credibility intervals are shown for 
each policy for each of 7 example risk scores.  The option with the highest expected net benefit at each risk score 
is identified in red.  For example, given a willingness to pay of £30,000 per QALY, the most cost-effective strategy 
for those with a risk score of 20 is a one-off FBSE, whilst those with a risk score of 30 should be enrolled in a 
monitoring programme with 3-yearly recall. 
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Figure 3: 95% credibility ellipse 
 
Central locus is the expected incremental cost and QALYs gained per person enrolled into the 
‘compound’ strategy in the UK.  Uncertainty in the point estimates is illustrated with the 95% 
credibility ellipse.  It is almost certain that the strategy will be cost increasing, but there is a great 
deal of uncertainty as to whether it will yield a health benefit. 
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Figure 4: Cost Effectiveness Acceptability Curve of Compound Risk-stratified policy vs Status Quo 
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Appendix 1: The Williams Self-Assessment Tool 
Box A1.1 Questions in the electronic self-assessed questionnaire 
 
  Severe sunburns 
 As a child between the ages of 2 and 10, how many sunburns did you have that were so severe they 
produced blisters or pain lasting two or more days? (none, 1-4, 5-9, 10 or more) 
 As a child between the ages of 11 and 18, how many sunburns did you have that were so severe they 
produced blisters or pain lasting two or more days? (none, 1-4, 5-9, 10 or more) 
 
Natural hair colour at age 15 
 What was your natural hair colour at age 15? (red, blond, light brown, dark brown, black) 
 
Freckles 
 Before the age of 20, which of the following best describes how many freckles you hand on your 
arms? Freckles are different from moles, usually found on the face and shoulders and more common 
in children and those with red hair and fair skin.  They fade in the winter months and are more 
numerous in individuals living closer to the equator. (none, few, several, a lot) 
 
Moles on the arms 
 Look at the skin on your left arm.  To do this you may need to remove a sweater or roll up your 
sleeves. Starting with your shoulder and moving down to the wrist, please look at the moles on your 
left arm. Of those moles, I would like you to determine how many are raised.  A raised mole is a 
brown or black spot or beauty mark, which may be large or small, which you can feel with your 
fingertips. Now run your fingertips over your left arm, and count any raised moles. Now do the same 
for your right arm. (none, 1, 2, 3 or more 
 
Prior non-melanoma skin cancer 
 Have you ever been told by a doctor that you have skin cancer other than melanoma? If yes, what 
type of skin cancer have you had? Squamous cell cancer (yes or no); basal cell (also known as rodent 
ulcer) (yes or no); melanoma (yes or no); other skin cancer (yes or no)  
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Box A1.2: Williams et al. (2011)12 melanoma risk score calculation (range 0-67) 
Risk factor Points    
Sex Female Male   
 0 7   
Age in years 35-44 45-54 55-64 65-74 
 0 5 8 11 
Number of severe 
sunburns ages 2-18 
None 1-4 5-9 10 or more 
 0 1 4 7 
Natural hair colour at 
age 15 
Dark 
brown/black 
Light brown Blond Red 
 0 4 5 8 
Density of freckles 
on arms before age 
20 
None A few Several A lot 
 0 4 6 10 
Number of raised 
moles on both arms 
None 1 2 3 or more 
 0 3 5 11 
Prior non-melanoma 
skin cancer 
No Yes   
 0 13   
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Appendix 2: Literature Review 
A review of the literature was conducted to estimate the prevalence of undiagnosed melanoma in the 
community.  The only study type able to provide an estimate (and hence inclusion criterion) is a 
population level screening programme.   
We conducted a review (September 2017) of PubMed with the search terms “population prevalence 
melanoma screen”, limited to studies published 2007-2017.  This identified 164 potentially relevant 
articles.  Review by title yielded 7 studies.  Review of abstract yielded one relevant study.18  This was 
a population screening study in Germany. 
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Appendix 3: Calculation of annual incidence and prevalence of melanoma as a 
function of Williams Self-Assessment Risk Score 
Data on age and gender specific incidence of malignant melanoma19 were weighted according to UK 
population statistics50 and re-categorised into age bands to match the risk score calculations (Table 
A3.1).12   
 
Table A3.1: Incidence of melanoma (per 100,000 per year) 
 Male Female 
<45 6.76 12.24 
45-54 30.17 38.81 
55-64 53.05 48.90 
65+ 110.72 74.06 
 
Data from the Melatools Q study,24 a cross-sectional study of 4040 members of the UK general 
population were combined with this to generate an annual probability of developing melanoma as a 
function of risk score.  Within each age/gender group, the odds ratio of melanoma was calculated as 
the sum of the log-odds-ratios for the scores on all questions except age and gender (e.g. as per Tables 
A3.2 – A3.4).  For example, the male in the first row of the sample data (risk score 24) has an odds 
ratio that is 10.07 times the lifetime odds of the lowest risk group (female, 35-44yo, no history of 
adolescent sunburn, dark brown/black hair, no freckles, no moles, no history of non-melanoma skin 
cancer), but 5.10 times the lifetime odds of the lowest risk within his age/gender group (male, 35-
44yo, no history of adolescent sunburn, dark brown/black hair, no freckles, no moles, no history of 
non-melanoma skin cancer). 
 
Table A3.2: Example Melatools-Q raw data 
gender_desc age_desc gender age hair moles freckles sunburns hx_scc 
Male <45 1 1 2 2 4 1 2 
Male <45 1 1 2 1 1 2 2 
Male <45 1 1 3 1 3 1 2 
Male <45 1 1 2 1 1 1 2 
Male <45 1 1 2 1 2 2 2 
 
Table A3.3: Associated Williams risk score 
gender_desc age_desc gender age hair moles freckles sunburns hx_scc Total 
Male <45 7 0 4 3 10 0 0 24 
Male <45 7 0 4 0 0 1 0 12 
Male <45 7 0 5 0 6 0 0 18 
Male <45 7 0 4 0 0 0 0 11 
Male <45 7 0 4 0 4 1 0 16 
 
Table A3.4: Associated log-ORs 
         
Vs lowest possible 
risk 
Vs lowest risk 
within age/gender 
group 
gender_desc age_desc gender age hair moles freckles sunburns hx_scc Ln(OR) OR Ln(OR) OR 
Male <45 0.68 0 0.39 0.25 0.99 0 0 2.31 10.07 1.63 5.10 
Male <45 0.68 0 0.39 0 0 0.09 0 1.16 3.19 0.48 1.62 
Male <45 0.68 0 0.45 0 0.63 0 0 1.76 5.81 1.08 2.94 
Male <45 0.68 0 0.39 0 0 0 0 1.07 2.92 0.39 1.48 
Male <45 0.68 0 0.39 0 0.44 0.09 0 1.6 4.95 0.92 2.51 
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Given the annual incidence of melanoma in each age/gender group, and the distribution of risk 
amongst that age group, it is possible to calculate the annual incidence by risk score.  This is because 
the weighted sum of the odds ratios for all individuals relative to the lowest risk, divided by the odds 
of melanoma for that lowest risk individual equals the odds for the group as a whole (equation A3.1).  
Rearranging the formula, the odds of the lowest risk individual is equal to the sum of the odds ratios 
divided by the mean odds for the group (equation A3.2).  The calculation with the five sample 
observations is shown in Table A3.4. 
 
Equation A3.1 
∑ 𝑤𝑖𝑂𝑅𝑖𝑖
𝑂𝑙
= ?̅? 
 
Equation A3.2 
𝑂𝑙 =
∑ 𝑤𝑖𝑂𝑅𝑖𝑖
?̅?
 
 
 
Table A3.5:  
gender_desc age_desc OR wi OR/n 
Male <45 5.10 0.2 0.012 
Male <45 1.62 0.2 0.0039 
Male <45 2.94 0.2 0.0070 
Male <45 1.48 0.2 0.0035 
Male <45 2.51 0.2 0.0060 
 ?̅?: 2.73 ∑ 𝑤𝑖𝑂𝑅𝑖𝑖 : 0.0324 
   
∑ 𝑤𝑖𝑂𝑅𝑖𝑖
?̅?
: 0.0119 
 
The odds of melanoma in <45yo males (Table A3.1) = P/(1-P) = 0.000068/(1+0.000068) = 0.000068 
Odds of melanoma in lowest risk members of group = Odds * 0.0119 = 0.000068 + 0.0119 = 
0.000000809 
 
This means that a 35-44yo male with no history of adolescent sunburn, dark brown/black hair, no 
freckles, no moles, no history of non-melanoma skin cancer (equating to a Williams risk score of 7) has 
an odds of 0.000000809 of melanoma per annum.  The log-odds is -14.027. 
 
We know the odds ratio of melanoma for every individual relative to someone with a risk score of 7, 
so it is simply a matter of calculating the probabilities from the odds ratios (Table A3.6). 
 
Table A3.6 
gender_desc age_desc Williams Score OR 
Ln(OR) Ln(Odds|sco
re=7) 
Ln(OR)+ 
Ln(Odds|sco
re=7) 
Odds Probability 
Male <45 24 5.10 1.629 -14.027 -12.398 0.00000412 0.000412% 
Male <45 12 1.62 0.482 -14.027 -13.545 0.00000131 0.000131% 
Male <45 18 2.94 1.078 -14.027 -12.949 0.00000238 0.000238% 
Male <45 11 1.48 0.392 -14.027 -13.635 0.00000120 0.000120% 
Male <45 16 2.51 0.920 -14.027 -13.107 0.00000203 0.000203% 
 
The probability of melanoma in lowest risk members of group (i.e. risk score 7) = O/(1+O) =  
0.000000809/(1+0.000000809) = 0.000000809 = 0.0000809%.  Note the probabilities in this example 
are artificially small due to only including 5 observations. 
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This was repeated for all age/gender groups in the MelatoolsQ data, and included participants with a 
range of risk scores between 0 and 49 (out of a theoretical maximum score of 67).  The mean 
probability by risk score was calculated and a log-linear model fit to the data.  This was repeated 
50,000 times in a Monte Carlo simulation, each time sampling from the distributions of coefficients 
on the Williams OR model (see Table 2, Williams et al. 201112).  The coefficients of the log-linear model 
were recorded each iteration, and the mean and standard deviation of these samples interpreted as 
the mean and standard error of the coefficients.  This yielded the parameters reported in Figure 1 
(repeated here): 
 
𝑃(𝑖𝑛𝑐𝑖𝑑𝑒𝑛𝑡 𝑚𝑒𝑙𝑎𝑛𝑜𝑚𝑎 𝑝𝑒𝑟 𝑎𝑛𝑛𝑢𝑚) =  𝑒(𝛼+𝛽𝑊) 
𝛼~𝑁(−10.270,0.186) 
𝛽~𝑁(0.117, 0.008) 
W = Williams risk score. 
 
Calculating Relative Risks 
Expected relative risk between two scores is estimated by calculating the ratio between the equation 
evaluated at two points.  For example, the expected incidence for a person with zero risk score = 
𝑒(−10.270+0) = 0.000035.  The expected incidence for a person with risk score 16 is 
𝑒(−10.270+0.117∗16) = 0.000225.  The relative risk of a person with score 16 vs 0 is 
0.000225
0.000035
= 6.4. 
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Appendix 4: Calculation of transition probabilities in undetected and hence 
untreated melanoma 
Data from the expert elicitation exercise20 are in the form of parameters for a series of scaled-beta 
distributed ‘Z’ parameters.  The relevant probabilities of these are estimated as products of the Z’s.  
This ensures correlations between the probabilities are preserved and that they sum to 1.  Note that 
for the purpose of the model risk of death was factored out of these distributions as mortality is 
calculated separately. 
For example, the Z parameters for the probability of moving from in situ LM to any other stage thought 
possible by the experts (in this case 6 other states) are reported as per Table A4.1.  Note the reported 
medians in Table A4.1 do not sum to 1 as they represent an aggregate of individual expert beliefs.  
However, each sampled set of probabilities does, by definition, sum to 1.  The ordering of the Z 
parameters must be preserved correctly calculate the probabilities. 
Table A4.1: Z parameters for modified CM distribution to sample transition probabilities from IS LM 
to IS LM, 1B, 1A, 2A, 2B and death 
From > To a B L U LL MED UL 
IS LM > IS LM 0.167 0.102 0.023 0.999 0.02 0.92 1.00 
IS LM > 1A 9.624 2.133 0.073 0.956 0.00 0.06 0.88 
IS LM > 1B 9.885 9.988 0.039 0.604 0.00 0.00 0.11 
IS LM > 2A 2.412 9.960 0.101 0.994 0.00 0.00 0.07 
IS LM > 2B 9.964 3.223 0.019 0.665 0.00 0.00 0.09 
IS LM > 2C 9.810 9.970 0.649 0.964 0.00 0.00 0.07 
IS LM > 3A n/a n/a n/a n/a 0.00 0.00 0.02 
LL = lower 95% Credibility limit; MED = median; UL = upper 95% credibility limit 
We sampled from a modified CM distribution20 with 6 Z-parameters (where the number of Z-
parameters is number of dimensions – 1). 
Thus: 
Z1 ~ ScaledBeta (0.167, 0.102, 0.023,0.999) 
Z2 ~ ScaledBeta (9.624, 2.133, 0.073, 0.956) 
Z3 ~ ScaledBeta (9.885, 9.988, 0.039, 0.604) 
Z4 ~ ScaledBeta (2.412, 9.960, 0.101, 0.994) 
Z5 ~ ScaledBeta (9.964, 3.223, 0.019, 0.665) 
Z6 ~ ScaledBeta (9.810, 9.970, 0.649, 0.964) 
 
And: 
P1 = P(IS LM > IS LM) = Z1 
P2 = P(IS LM > 1A) = Z2(1-Z1) 
P3 = P(IS LM > 1B) = Z3(1-Z2)(1-Z1) 
P4 = P(IS LM > 2A) = Z4(1-Z3)(1-Z2)(1-Z1) 
P5 = P(IS LM > 2B) = Z5(1-Z4)(1-Z3)(1-Z2)(1-Z1) 
P6 = P(IS LM > 2C) = Z6(1-Z5)(1-Z4)(1-Z3)(1-Z2)(1-Z1) 
P7 = P(IS LM > 3A) = (1-Z6)(1-Z5)(1-Z4)(1-Z3)(1-Z2)(1-Z1) 
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Where P1 is the probability of remaining in ISLM, P2 is the probability of progressing to 1A etc. 
 
The simplest approach to calculating the marginal probability distributions is to sample a large number 
of sets of probabilities and calculate the empirical median, lower and upper 95% credibility limits as 
shown in Table A4.2.  The estimated medians and 95% credibility intervals match the elicited values 
in Table A4.1, suggesting the sampling has worked. 
Table A4.2: Z parameters for modified CM distribution to sample transition probabilities from IS LM 
to IS LM, 1B, 1A, 2A, and 2B, and estimated mean, median and 95%CrI(6m probabilities) 
 Z hyper-parameters Associated probabilities 
From > To a b L U median 95% CrI 
IS LM > IS LM 0.167 0.102 0.023 0.999 0.92 (0.02, 1.00) 
IS LM > 1A 9.624 2.133 0.073 0.956 0.06 (0.00, 0.88) 
IS LM > 1B 9.885 9.988 0.039 0.604 0.00 (0.00, 0.11) 
IS LM > 2A 2.412 9.960 0.101 0.994 0.00 (0.00, 0.07) 
IS LM > 2B 9.964 3.223 0.019 0.665 0.00 (0.00, 0.09) 
IS LM > 2C 9.810 9.970 0.649 0.964 0.00 (0.00, 0.07) 
IS LM > 3A n/a n/a n/a n/a 0.00 (0.00, 0.02) 
 
These represent the elicited transition probabilities over six months.  The transition period in the 
model is 12 months therefore to adjust to 12 month transitions, the following edit was made: 
12m probability of remaining in the same state, e.g. P(ISLN>ISLM)12 = P(ISLM > ISLM)6^2 
12m probability of moving to another state 
eg P(ISLM>1B)12 = P(ISLM>1B)6 + (P(ISLM > ISLM)6 * P(ISLM>1B)6) 
where subscript 6 = 6 month probability; 12 = 12 month probability.  Resulting probabilities are in 
table A4.3. 
Table A4.3: Z parameters for modified CM distribution to sample transition probabilities from IS LM 
to IS LM, 1B, 1A, 2A, and 2B, and estimated mean, median and 95%CrI over 12m 
 Z-hyper-parameters Associated probabilities (12m) 
From > To a b L U mean median 95% CrI 
IS LM > IS LM 0.167 0.102 0.023 0.999 0.637 0.674 (0.123, 0.985) 
IS LM > 1A 9.624 2.133 0.073 0.956 0.103 0.092 (0.004, 0.249) 
IS LM > 1B 9.885 9.988 0.039 0.604 0.150 0.104 (0.002, 0.515) 
IS LM > 2A 2.412 9.960 0.101 0.994 0.072 0.040 (0.000, 0.298) 
IS LM > 2B 9.964 3.223 0.019 0.665 0.038 0.021 (0.000, 0.157) 
IS LM > 2B 9.810 9.970 0.649 0.964 0.038 0.021 (0.000, 0.157) 
IS LM > 2B n/a n/a n/a n/a 0.038 0.021 (0.000, 0.157) 
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Appendix 5: UK specific Lifetables 
Source: ONS, Life tables for UK, 2012-1425 
Age Male Female Age Male Female Age Male Female 
0 0.004352 0.00357 34 0.000924 0.000538 68 0.016131 0.010748 
1 0.00033 0.000257 35 0.001016 0.000564 69 0.01797 0.011719 
2 0.000177 0.00013 36 0.001047 0.0006 70 0.019796 0.013122 
3 0.000116 0.000114 37 0.001176 0.000635 71 0.022073 0.014429 
4 0.000098 0.000087 38 0.001355 0.000732 72 0.025273 0.016475 
5 0.000098 0.000087 39 0.00142 0.000822 73 0.027243 0.018281 
6 0.000093 0.000081 40 0.001576 0.000883 74 0.029995 0.020211 
7 0.00009 0.000079 41 0.001626 0.000957 75 0.033205 0.022532 
8 0.000083 0.000069 42 0.00169 0.001058 76 0.036573 0.025116 
9 0.00009 0.000066 43 0.001882 0.001156 77 0.040211 0.028226 
10 0.000095 0.000075 44 0.002062 0.00127 78 0.045461 0.031273 
11 0.000094 0.000065 45 0.002248 0.001382 79 0.049611 0.035843 
12 0.000109 0.000066 46 0.00236 0.001446 80 0.056322 0.040816 
13 0.000115 0.000093 47 0.002502 0.001622 81 0.06328 0.045772 
14 0.000131 0.000106 48 0.002677 0.00171 82 0.071519 0.051697 
15 0.000147 0.000128 49 0.00294 0.001924 83 0.079828 0.058965 
16 0.000215 0.000143 50 0.003101 0.002156 84 0.089056 0.067661 
17 0.000308 0.00016 51 0.003423 0.002344 85 0.100248 0.076098 
18 0.000443 0.000183 52 0.003702 0.002558 86 0.111772 0.085623 
19 0.000477 0.000198 53 0.004067 0.00278 87 0.123954 0.096404 
20 0.000467 0.000202 54 0.004528 0.002977 88 0.137712 0.106974 
21 0.000473 0.000207 55 0.004865 0.003402 89 0.152512 0.122022 
22 0.000468 0.000214 56 0.005353 0.003674 90 0.166455 0.136144 
23 0.000555 0.000232 57 0.005962 0.004033 91 0.182981 0.151001 
24 0.000521 0.000227 58 0.006607 0.004385 92 0.208161 0.171558 
25 0.000559 0.000255 59 0.007416 0.004772 93 0.222733 0.185224 
26 0.000641 0.000259 60 0.008002 0.005226 94 0.231918 0.2023 
27 0.00062 0.000274 61 0.008809 0.005808 95 0.259055 0.219153 
28 0.000627 0.000343 62 0.009679 0.006283 96 0.286001 0.251076 
29 0.000709 0.000321 63 0.01034 0.006755 97 0.308416 0.2675 
30 0.000755 0.00037 64 0.011306 0.007356 98 0.33083 0.289642 
31 0.000793 0.000422 65 0.012111 0.007936 99 0.347717 0.315701 
32 0.000796 0.000424 66 0.013191 0.008579 100 0.35592 0.329873 
33 0.000875 0.000469 67 0.014606 0.009639    
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Appendix 6: Odds Ratio of survival as a function of disease stage at diagnosis 
Five year survival data were extracted from Figure 1, panels B&D, and Figure 2, panel A of Balch et 
al.22  The odds ratio of all stages vs 1A was then calculated, as well as the log-OR and standard error 
of log-OR.  We assumed that stage 1A disease has no impact on overall survival,51 then the annual 
probability of death is calculated as the age/gender baseline rate for the general population, adjusted 
for the odds ratio.  This is calculated by converting the probability into odds, summing the log-odds 
and the log-odds-ratio, exponentiating and converting back into a probability. 
For example, the baseline probability of death for a 40-year-old male is 0.1576%, whereas the 
probability of death for a 40-year-old male with stage 3A melanoma is 2.23% (Table A6.2). 
 
Table A6.1: Relative Odds of death as a function of disease stage 
 5yr         
 survival p dead alive sum Odds of death OR vs 1A Ln(OR) SE(Ln(OR)) 
1A 0.98 189 9263 9452 0.020 1   
1B 0.92 713 8205 8918 0.087 4.261 1.449 0.007 
2A 0.8 929 3715 4644 0.250 12.250 2.506 0.007 
2B 0.7 968 2260 3228 0.429 21.000 3.045 0.007 
2C 0.54 643 754 1397 0.852 41.741 3.731 0.008 
3A 0.78 263 933 1196 0.282 13.821 2.626 0.010 
3B 0.6 556 835 1391 0.667 32.667 3.486 0.008 
3C 0.42 418 302 720 1.381 67.667 4.215 0.011 
4 0.136 6890 1082 7972 6.369 312.104 5.743 0.006 
         
 
Table A6.2: Calculating probability of death for a 40-year-old male with stage 3A melanoma 
Operation Equation Calculation 
Convert to odds 
𝑂 =
𝑃
(1 − 𝑃)
 
0.001576
(1 − 0.001576)
= 0.00158 
Take the natural log ln (𝑂) ln(0.00158) = −6.451 
Sum the log OR ln(𝑂) + ln (𝑂𝑅) -6.451 + 2.626 = -3.825 
Exponentiate 𝑒ln(𝑂)+ln (𝑂𝑅) 𝑒−3.808 = 0.022 
Convert to probability 
𝑃 =
𝑂
(1 + 𝑂)
 
0.022
(1 − 0.022)
= 0.0223 
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Appendix 7: Opportunistic presentation rate 
The opportunistic presentation rate was determined as follows.  In 2013 there were 14509 cases of 
melanoma diagnosed.1  An estimated 12% of cases referred to secondary care are melanoma.27  This 
implies that there were approximately 120908 referrals in the UK (=14509*0.12).  An estimated 26% 
of patients presenting in primary care are referred to secondary care,26 suggesting 465031 patients 
presented in primary care.  The UK population in 2013 was estimated at 64,105,654.23  Therefore 
0.725% of the population presented in primary care with a mole they were concerned about. 
 
Nr melanoma cases 2013  14509 Cancer Research UK1 
% of referred cases that are melanoma 12%  Cox et al. 200427 
Inferred number of referrals   120908  
% patients presenting in primary care referred 
to secondary 
26%  Molemate data – per patient 
(not lesion) basis.26 
Inferred number of patients presenting in 
primary care 
 465031  
UK population in 2013  64105654 Office for National Statistics23 
% of population presenting in primary care  0.725%  
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Appendix 8: Costs of treatment by disease stage and costs in final year of life. 
Treatment costs are based on 2010 UK guidelines,31 and are calculated using the same approach the 
authors used in a previous study.14  The text and table A8.1 below are based on Wilson et al.14 with 
updated unit costs. 
Patients who undergo any intervention in secondary care firstly undergo biopsy excision (at which 
point the disease is staged according to AJCC guidelines22), followed by definitive surgery.  Patients 
with stage 0, Ia and Ib disease undergo no further treatment.  Patients with stage IIa and higher disease 
undergo sentinel lymph node biopsy, and patients with stage IIb and higher disease also undergo chest 
x-ray, CT scan, liver function test and full blood count.  Patients with a positive sentinel node biopsy 
undergo follow-up surgery for lymph node involvement, comprising pre-operative CT scan and radical 
lymph node basin dissection.  Patients with stage IV disease undergo surgery for removal of localised 
metastases, a course of 10 fractions of radiotherapy and 6 cycles of dacarbazine-based chemotherapy. 
Follow-up 
It is recommended that patients with in-situ (Stage 0) disease have only 1 follow-up appointment.  
Patients with stage I disease should be followed up every three months for three years before 
discharge (total 12 visits), and patients with stage II followed up as per stage I, followed by twice-
yearly checks for a further two years (total 16 visits).31  For ease of modelling, the discounted cost of 
all these visits was added to the first year cost. 
Terminal care costs 
In the model, patients with stage 0 or Ia disease have a normal lifespan.  Therefore, it is assumed they 
do not die as a result of their disease.  Patients with stage Ib disease and above have a reduced life 
expectancy and are therefore assumed to die as a result of their disease.  Previous studies of lifetime 
melanoma-related costs of melanoma patients show peaks in resource consumption at initial 
treatment and terminal phase for all patients, irrespective of stage at diagnosis.52  Therefore the costs 
in the final year of life for patients with Ib disease and above are assumed to be the same as for the 
treatment of metastatic disease (surgical removal of localised metastases, radiotherapy and 
chemotherapy). 
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Table A8.1 - Treatment and terminal care costs (means) 
 unit cost 0 1a 1b 2a 2b 2c 3a 3b 3c 4 
Initial treatment            
Biopsy excision £143.00 1 1 1 1 1 1 1 1 1 1 
Definitive surgery £156.00 1 1 1 1 1 1 1 1 1 1 
Investigations            
CXR £30.00     1 1 1 1 1 1 
CT scan £132.00     1 1 1 1 1 1 
Liver function test £3.00     1 1 1 1 1 1 
FBC £3.00     1 1 1 1 1 1 
Sentinel node biopsy (carried out at 
same time as definitive surgery) £29.00    1 1 1 1 1 1 1 
            
Follow-up surgery for positive lymph 
nodes            
pre-operative CT scan £132.00       1 1 1  
radical lymph node dissection £991.00       1 1 1  
            
Metastatic disease            
Surgical removal of localised 
metastases £725.00          1 
Radiotherapy £2,055.00          1 
Chemotherapy (dacarbazine) £1,485.00          1 
            
Follow-up            
single follow-up £97.00 1          
3 monthly for 3 years then discharge 
= 12 visits £1,164.00  1 1        
3 monthly for 3 yrs then 2 yrly for 2 
yrs = 16 visits £1,552.00    1 1 1 1 1 1 1 
            
Terminal care            
Assume same as metastatic disease £4,265.00   1 1 1 1 1 1 1 1 
            
Year 1 cost  £396.00 £1,463.00 £1,463.00 £1,880.00 £2,048.00 £2,048.00 £3,171.00 £3,171.00 £3,171.00 £4,761.00 
Terminal year cost  £0.00 £0.00 £4,265.00 £4,265.00 £4,265.00 £4,265.00 £4,265.00 £4,265.00 £4,265.00 £4,265.00 
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Appendix 9: Model Stability 
Stability of the model was determined by calculating the coefficient of variation (CoV) of estimates of 
the expected cost and QALYs and standard error of mean cost and QALYs from 50 repeated iterations, 
using different numbers of simulations and cohort sizes for one of the modelled scenarios.  For 
example, the model was set to simulate the ‘do nothing’ scenario in a cohort of 1000 patients, 10 
times and the expected and SE cost and QALYs recorded.  This was repeated 50 times and the CoV for 
mean cost was 3.44%, for the standard error of cost 24.12%, for mean QALYs 0.11% and SE of QALYs, 
25.97%. 
A ‘rule of thumb’ of a CoV of around 2% or below was considered sufficiently stable.  The CoV was 
much more sensitive to the number of simulations rather than the cohort size (Table A9.1).  1000 
simulations of a 1000-patient cohort provided sufficient stability whilst not consuming excessive 
computational time. 
Table A9.1: Coefficient of variation of mean cost, SE of mean cost, mean QALYs and SE of mean 
QALYs from various numbers of simulations and cohort sizes. 
 simulations cohortsize mean£ SE£ mQALY SEQALY 
1 10 1000 3.44 24.12 0.11 25.97 
2 10 1000 3.5 27.66 0.12 22.3 
3 10 5000 3.32 21.96 0.05 27.46 
4 10 10000 4.21 26.29 0.03 25.03 
5 10 25000 3.78 25.52 0.02 26.86 
6 20 1000 2.84 16.82 0.09 14.84 
7 30 1000 1.97 12.35 0.07 11.98 
8 50 1000 1.97 11.56 0.06 12 
9 70 1000 1.73 9.66 0.05 8.54 
10 90 1000 1.33 8.17 0.04 6.88 
11 100 1000 0.99 6.68 0.03 7.9 
12 100 2000 1.12 6.96 0.03 5.81 
13 250 1000 0.9 5.41 0.02 4.09 
14 500 1000 0.63 3.57 0.02 3.06 
15 1000 1000 0.39 2.21 0.01 1.93 
16 2000 1000 0.27 1.55 0.01 1.35 
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Appendix 10: Expected Cost, QALYs and Net Benefit of each policy by risk score 
The model was calculated at risk scores of 10, 17, 20, 25, 30, 50 and 60, and weighted according the 
distribution of risk scores in the UK.24  Interim risk scores were calculated by linear interpolation.  Net 
benefit was calculated at £20,000 and £30,000 per QALY gained.  The policy yielding the highest net 
benefit for each risk score is mathematically identical to the policy with the highest incremental cost-
effectiveness ratio below the threshold after taking into account dominated and extended-dominated 
strategies.  The most cost-effective strategy for each risk score is highlighted in bold.  Where there is 
a difference in recommendation at the £20,000 and £30,000 thresholds, both policies are highlighted.  
This occurs where the incremental cost-effectiveness ratio of the optimal strategy compared with the 
next best (non-dominated) option is between £20,000 and £30,000, thus would be rejected at the 
£20,000 threshold but accepted at £30,000. 
Table A10.1: Cost, QALYs and net benefit by risk score 
      
 
@£20,000 per QALY @£30,000 per QALY 
Risk Strategy  Cost SE(Cost) QALYs SE(QALYs) 
Cov(£, 
QALYs) NB SE(NB) NB SE(NB) 
  10 Do nothing £21.22 £5.14 17.532 0.287 -0.295 £350,613.37 £1,810.58 £525,930.66 £2,715.68 
 One off exam £147.57 £18.30 17.533 0.286 -0.282 £350,512.07 £1,768.01 £525,841.90 £2,651.87 
 monitor every 5 years £407.19 £50.43 17.536 0.284 0.900 £350,315.39 £1,819.50 £525,676.68 £2,729.20 
 monitor every 4 years £494.19 £61.40 17.537 0.283 1.344 £350,241.18 £1,788.23 £525,608.86 £2,682.01 
 monitor every 3 years £658.61 £81.84 17.539 0.284 1.986 £350,120.79 £1,803.34 £525,510.49 £2,704.73 
 monitor every 2 years £930.45 £115.67 17.538 0.283 2.781 £349,832.12 £1,798.58 £525,213.40 £2,696.66 
 Annual monitor £2,206.62 £276.04 17.537 0.286 9.029 £348,537.01 £1,801.90 £523,908.83 £2,688.90 
11 Do nothing £21.88 £5.45 17.530 0.259 -0.265 £350,580.93 £1,810.73 £525,882.34 £2,715.87 
 One off exam £147.94 £18.30 17.532 0.258 -0.247 £350,492.65 £1,774.47 £525,812.94 £2,661.54 
 monitor every 5 years £406.93 £50.15 17.535 0.256 0.775 £350,299.28 £1,816.34 £525,652.39 £2,724.40 
 monitor every 4 years £493.70 £61.04 17.536 0.255 1.159 £350,226.46 £1,790.82 £525,586.54 £2,685.86 
 monitor every 3 years £657.71 £81.33 17.538 0.257 1.727 £350,105.50 £1,801.84 £525,487.10 £2,702.45 
 monitor every 2 years £928.86 £114.98 17.537 0.256 2.414 £349,818.25 £1,801.05 £525,191.81 £2,700.32 
 Annual monitor £2,201.75 £274.27 17.537 0.259 7.866 £348,538.31 £1,807.89 £523,908.33 £2,698.33 
12 Do nothing £22.54 £5.76 17.529 0.231 -0.234 £350,548.50 £1,810.88 £525,834.02 £2,716.06 
 One off exam £148.30 £18.30 17.531 0.230 -0.212 £350,473.23 £1,780.93 £525,783.99 £2,671.21 
 monitor every 5 years £406.68 £49.87 17.534 0.229 0.651 £350,283.17 £1,813.17 £525,628.09 £2,719.61 
 monitor every 4 years £493.20 £60.68 17.535 0.228 0.973 £350,211.75 £1,793.41 £525,564.22 £2,689.72 
 monitor every 3 years £656.81 £80.82 17.537 0.229 1.468 £350,090.21 £1,800.34 £525,463.71 £2,700.17 
 monitor every 2 years £927.26 £114.30 17.537 0.228 2.048 £349,804.39 £1,803.53 £525,170.21 £2,703.97 
 Annual monitor £2,196.87 £272.49 17.537 0.231 6.703 £348,539.60 £1,813.89 £523,907.84 £2,707.76 
13 Do nothing £23.20 £6.08 17.527 0.203 -0.204 £350,516.06 £1,811.04 £525,785.69 £2,716.25 
 One off exam £148.66 £18.30 17.530 0.202 -0.177 £350,453.81 £1,787.38 £525,755.04 £2,680.88 
 monitor every 5 years £406.43 £49.59 17.534 0.201 0.527 £350,267.05 £1,810.01 £525,603.79 £2,714.82 
 monitor every 4 years £492.70 £60.32 17.534 0.200 0.787 £350,197.03 £1,796.00 £525,541.90 £2,693.58 
 monitor every 3 years £655.90 £80.31 17.537 0.201 1.209 £350,074.92 £1,798.84 £525,440.33 £2,697.90 
 monitor every 2 years £925.66 £113.62 17.536 0.201 1.681 £349,790.52 £1,806.01 £525,148.61 £2,707.62 
 Annual monitor £2,191.99 £270.72 17.537 0.203 5.540 £348,540.90 £1,819.89 £523,907.35 £2,717.19 
14 Do nothing £23.86 £6.39 17.525 0.175 -0.173 £350,483.63 £1,811.19 £525,737.37 £2,716.44 
 One off exam £149.02 £18.30 17.529 0.174 -0.141 £350,434.38 £1,793.84 £525,726.09 £2,690.55 
 monitor every 5 years £406.17 £49.32 17.533 0.173 0.402 £350,250.94 £1,806.85 £525,579.49 £2,710.03 
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 monitor every 4 years £492.20 £59.95 17.534 0.173 0.601 £350,182.32 £1,798.59 £525,519.58 £2,697.43 
 monitor every 3 years £655.00 £79.80 17.536 0.173 0.950 £350,059.62 £1,797.33 £525,416.94 £2,695.62 
 monitor every 2 years £924.06 £112.93 17.535 0.173 1.315 £349,776.66 £1,808.48 £525,127.02 £2,711.27 
 Annual monitor £2,187.12 £268.95 17.536 0.175 4.377 £348,542.20 £1,825.88 £523,906.85 £2,726.61 
15 Do nothing £24.52 £6.70 17.524 0.147 -0.142 £350,451.19 £1,811.35 £525,689.05 £2,716.64 
 One off exam £149.39 £18.29 17.528 0.146 -0.106 £350,414.96 £1,800.30 £525,697.13 £2,700.21 
 monitor every 5 years £405.92 £49.04 17.532 0.145 0.278 £350,234.82 £1,803.69 £525,555.20 £2,705.24 
 monitor every 4 years £491.70 £59.59 17.533 0.145 0.416 £350,167.61 £1,801.19 £525,497.26 £2,701.29 
 monitor every 3 years £654.10 £79.29 17.535 0.145 0.691 £350,044.33 £1,795.83 £525,393.55 £2,693.34 
 monitor every 2 years £922.46 £112.25 17.534 0.146 0.948 £349,762.79 £1,810.96 £525,105.42 £2,714.92 
 Annual monitor £2,182.24 £267.18 17.536 0.147 3.214 £348,543.49 £1,831.88 £523,906.36 £2,736.04 
16 Do nothing £25.18 £7.02 17.522 0.119 -0.112 £350,418.76 £1,811.50 £525,640.72 £2,716.83 
 One off exam £149.75 £18.29 17.527 0.118 -0.071 £350,395.54 £1,806.76 £525,668.18 £2,709.88 
 monitor every 5 years £405.67 £48.76 17.531 0.118 0.153 £350,218.71 £1,800.52 £525,530.90 £2,700.45 
 monitor every 4 years £491.20 £59.23 17.532 0.118 0.230 £350,152.89 £1,803.78 £525,474.94 £2,705.14 
 monitor every 3 years £653.20 £78.78 17.534 0.117 0.432 £350,029.04 £1,794.33 £525,370.16 £2,691.06 
 monitor every 2 years £920.86 £111.56 17.533 0.118 0.581 £349,748.93 £1,813.44 £525,083.83 £2,718.58 
 Annual monitor £2,177.36 £265.40 17.536 0.120 2.051 £348,544.79 £1,837.87 £523,905.87 £2,745.47 
17 Do nothing £25.84 £7.33 17.521 0.091 -0.081 £350,386.32 £1,811.65 £525,592.40 £2,717.02 
 One off exam £150.11 £18.29 17.526 0.091 -0.036 £350,376.11 £1,813.22 £525,639.23 £2,719.55 
 monitor every 5 years £405.42 £48.48 17.530 0.090 0.029 £350,202.60 £1,797.36 £525,506.60 £2,695.65 
 monitor every 4 years £490.70 £58.86 17.531 0.090 0.044 £350,138.18 £1,806.37 £525,452.61 £2,709.00 
 monitor every 3 years £652.30 £78.27 17.533 0.090 0.173 £350,013.75 £1,792.83 £525,346.77 £2,688.79 
 monitor every 2 years £919.26 £110.88 17.533 0.091 0.215 £349,735.07 £1,815.91 £525,062.23 £2,722.23 
 Annual monitor £2,172.48 £263.63 17.536 0.092 0.888 £348,546.09 £1,843.87 £523,905.37 £2,754.90 
18 Do nothing £26.95 £7.76 17.518 0.091 -0.096 £350,337.06 £1,818.49 £525,519.06 £2,727.19 
 One off exam £151.40 £18.57 17.524 0.091 -0.051 £350,321.72 £1,818.04 £525,558.29 £2,726.70 
 monitor every 5 years £406.79 £48.86 17.529 0.090 0.034 £350,167.75 £1,798.17 £525,455.02 £2,696.88 
 monitor every 4 years £492.22 £59.29 17.530 0.090 0.042 £350,105.05 £1,804.87 £525,403.69 £2,706.73 
 monitor every 3 years £653.72 £78.83 17.531 0.090 0.181 £349,971.03 £1,796.58 £525,283.40 £2,694.44 
 monitor every 2 years £920.69 £111.50 17.532 0.091 0.142 £349,712.45 £1,817.51 £525,029.01 £2,724.20 
 Annual monitor £2,174.10 £265.02 17.534 0.091 0.870 £348,514.97 £1,832.78 £523,859.50 £2,737.93 
19 Do nothing £28.05 £8.19 17.516 0.091 -0.112 £350,287.80 £1,825.33 £525,445.73 £2,737.37 
 One off exam £152.70 £18.86 17.521 0.091 -0.066 £350,267.34 £1,822.86 £525,477.35 £2,733.84 
 monitor every 5 years £408.17 £49.23 17.527 0.090 0.038 £350,132.90 £1,798.97 £525,403.44 £2,698.11 
 monitor every 4 years £493.74 £59.71 17.528 0.090 0.039 £350,071.93 £1,803.37 £525,354.77 £2,704.45 
 monitor every 3 years £655.13 £79.38 17.529 0.090 0.189 £349,928.31 £1,800.33 £525,220.03 £2,700.09 
 monitor every 2 years £922.11 £112.12 17.531 0.091 0.068 £349,689.83 £1,819.12 £524,995.80 £2,726.17 
 Annual monitor £2,175.71 £266.41 17.533 0.091 0.852 £348,483.84 £1,821.69 £523,813.62 £2,720.96 
20 Do nothing £29.16 £8.62 17.513 0.092 -0.127 £350,238.55 £1,832.17 £525,372.40 £2,747.55 
 One off exam £153.99 £19.15 17.518 0.091 -0.080 £350,212.95 £1,827.68 £525,396.41 £2,740.99 
 monitor every 5 years £409.55 £49.61 17.525 0.090 0.043 £350,098.06 £1,799.78 £525,351.86 £2,699.34 
 monitor every 4 years £495.26 £60.13 17.527 0.090 0.037 £350,038.81 £1,801.87 £525,305.85 £2,702.18 
 monitor every 3 years £656.55 £79.94 17.527 0.090 0.196 £349,885.58 £1,804.08 £525,156.65 £2,705.74 
 monitor every 2 years £923.53 £112.74 17.530 0.091 -0.005 £349,667.21 £1,820.72 £524,962.58 £2,728.14 
 Annual monitor £2,177.32 £267.80 17.532 0.090 0.834 £348,452.72 £1,810.60 £523,767.74 £2,703.98 
21 Do nothing £31.10 £9.64 17.509 0.092 -0.173 £350,155.98 £1,846.72 £525,249.52 £2,769.12 
 One off exam £155.81 £19.70 17.515 0.092 -0.120 £350,149.15 £1,834.00 £525,301.63 £2,750.26 
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 monitor every 5 years £411.13 £49.68 17.523 0.090 0.022 £350,049.68 £1,807.69 £525,280.08 £2,711.09 
 monitor every 4 years £496.51 £60.20 17.524 0.090 0.014 £349,991.24 £1,804.58 £525,235.12 £2,706.12 
 monitor every 3 years £657.29 £79.81 17.525 0.090 0.161 £349,840.71 £1,807.88 £525,089.71 £2,711.24 
 monitor every 2 years £923.55 £112.56 17.528 0.091 0.048 £349,637.68 £1,817.49 £524,918.29 £2,723.59 
 Annual monitor £2,173.98 £267.44 17.530 0.090 0.949 £348,427.76 £1,815.89 £523,728.62 £2,712.62 
22 Do nothing £33.05 £10.67 17.505 0.093 -0.219 £350,073.42 £1,861.26 £525,126.65 £2,790.70 
 One off exam £157.63 £20.25 17.512 0.092 -0.160 £350,085.36 £1,840.32 £525,206.85 £2,759.52 
 monitor every 5 years £412.70 £49.76 17.521 0.091 0.001 £350,001.29 £1,815.60 £525,208.29 £2,722.85 
 monitor every 4 years £497.77 £60.27 17.522 0.090 -0.009 £349,943.67 £1,807.29 £525,164.38 £2,710.06 
 monitor every 3 years £658.02 £79.68 17.523 0.091 0.126 £349,795.84 £1,811.67 £525,022.76 £2,716.74 
 monitor every 2 years £923.56 £112.38 17.527 0.091 0.101 £349,608.14 £1,814.25 £524,873.99 £2,719.04 
 Annual monitor £2,170.64 £267.07 17.529 0.091 1.063 £348,402.79 £1,821.18 £523,689.50 £2,721.25 
23 Do nothing £35.00 £11.70 17.501 0.094 -0.265 £349,990.85 £1,875.81 £525,003.78 £2,812.27 
 One off exam £159.45 £20.79 17.509 0.092 -0.199 £350,021.57 £1,846.64 £525,112.07 £2,768.79 
 monitor every 5 years £414.28 £49.83 17.518 0.091 -0.019 £349,952.91 £1,823.52 £525,136.50 £2,734.60 
 monitor every 4 years £499.02 £60.34 17.520 0.090 -0.031 £349,896.10 £1,810.01 £525,093.65 £2,714.00 
 monitor every 3 years £658.76 £79.55 17.520 0.091 0.090 £349,750.96 £1,815.46 £524,955.82 £2,722.24 
 monitor every 2 years £923.58 £112.20 17.525 0.090 0.154 £349,578.60 £1,811.02 £524,829.69 £2,714.48 
 Annual monitor £2,167.29 £266.71 17.527 0.091 1.177 £348,377.83 £1,826.46 £523,650.39 £2,729.88 
24 Do nothing £36.94 £12.72 17.497 0.094 -0.312 £349,908.29 £1,890.35 £524,880.90 £2,833.85 
 One off exam £161.27 £21.34 17.506 0.093 -0.239 £349,957.77 £1,852.96 £525,017.29 £2,778.06 
 monitor every 5 years £415.85 £49.90 17.516 0.092 -0.040 £349,904.53 £1,831.43 £525,064.72 £2,746.36 
 monitor every 4 years £500.27 £60.40 17.517 0.091 -0.054 £349,848.52 £1,812.72 £525,022.92 £2,717.94 
 monitor every 3 years £659.49 £79.42 17.518 0.091 0.055 £349,706.09 £1,819.25 £524,888.88 £2,727.73 
 monitor every 2 years £923.60 £112.02 17.524 0.090 0.207 £349,549.06 £1,807.79 £524,785.39 £2,709.93 
 Annual monitor £2,163.95 £266.35 17.526 0.091 1.291 £348,352.86 £1,831.75 £523,611.27 £2,738.51 
25 Do nothing £38.89 £13.75 17.493 0.095 -0.358 £349,825.72 £1,904.90 £524,758.03 £2,855.42 
 One off exam £163.09 £21.89 17.503 0.093 -0.278 £349,893.98 £1,859.29 £524,922.51 £2,787.32 
 monitor every 5 years £417.42 £49.98 17.514 0.092 -0.060 £349,856.15 £1,839.34 £524,992.93 £2,758.11 
 monitor every 4 years £501.52 £60.47 17.515 0.091 -0.076 £349,800.95 £1,815.43 £524,952.19 £2,721.88 
 monitor every 3 years £660.23 £79.29 17.516 0.091 0.019 £349,661.21 £1,823.04 £524,821.93 £2,733.23 
 monitor every 2 years £923.62 £111.84 17.522 0.090 0.260 £349,519.52 £1,804.55 £524,741.09 £2,705.38 
 Annual monitor £2,160.61 £265.99 17.524 0.092 1.405 £348,327.90 £1,837.03 £523,572.15 £2,747.14 
26 Do nothing £42.92 £15.65 17.485 0.096 -0.489 £349,666.89 £1,929.93 £524,521.80 £2,892.34 
 One off exam £166.99 £23.04 17.497 0.094 -0.391 £349,769.06 £1,881.85 £524,737.09 £2,820.60 
 monitor every 5 years £420.92 £50.39 17.509 0.092 -0.105 £349,754.72 £1,842.93 £524,842.54 £2,763.26 
 monitor every 4 years £504.88 £60.65 17.511 0.091 -0.106 £349,707.25 £1,821.20 £524,813.31 £2,730.37 
 monitor every 3 years £663.45 £79.46 17.513 0.091 0.003 £349,590.36 £1,824.76 £524,717.26 £2,735.72 
 monitor every 2 years £926.68 £111.85 17.518 0.090 0.254 £349,436.79 £1,807.29 £524,618.53 £2,709.46 
 Annual monitor £2,163.80 £265.60 17.521 0.091 1.310 £348,250.71 £1,834.19 £523,457.96 £2,742.38 
27 Do nothing £46.95 £17.54 17.478 0.097 -0.621 £349,508.07 £1,954.97 £524,285.57 £2,929.26 
 One off exam £170.89 £24.20 17.491 0.095 -0.504 £349,644.15 £1,904.41 £524,551.67 £2,853.88 
 monitor every 5 years £424.41 £50.81 17.504 0.092 -0.150 £349,653.30 £1,846.53 £524,692.16 £2,768.40 
 monitor every 4 years £508.24 £60.84 17.506 0.091 -0.136 £349,613.54 £1,826.97 £524,674.43 £2,738.87 
 monitor every 3 years £666.67 £79.62 17.509 0.091 -0.013 £349,519.51 £1,826.48 £524,612.59 £2,738.21 
 monitor every 2 years £929.75 £111.86 17.514 0.090 0.247 £349,354.06 £1,810.04 £524,495.96 £2,713.54 
 Annual monitor £2,166.98 £265.22 17.517 0.091 1.214 £348,173.52 £1,831.34 £523,343.77 £2,737.61 
28 Do nothing £50.97 £19.44 17.470 0.099 -0.752 £349,349.24 £1,980.01 £524,049.35 £2,966.18 
43 
 
 One off exam £174.79 £25.35 17.485 0.096 -0.617 £349,519.23 £1,926.97 £524,366.24 £2,887.15 
 monitor every 5 years £427.90 £51.23 17.499 0.092 -0.195 £349,551.88 £1,850.12 £524,541.77 £2,773.54 
 monitor every 4 years £511.60 £61.02 17.502 0.091 -0.165 £349,519.84 £1,832.74 £524,535.55 £2,747.36 
 monitor every 3 years £669.89 £79.78 17.506 0.091 -0.029 £349,448.65 £1,828.21 £524,507.92 £2,740.70 
 monitor every 2 years £932.82 £111.87 17.510 0.091 0.240 £349,271.32 £1,812.78 £524,373.40 £2,717.62 
 Annual monitor £2,170.17 £264.84 17.513 0.091 1.119 £348,096.33 £1,828.49 £523,229.58 £2,732.85 
29 Do nothing £55.00 £21.34 17.462 0.100 -0.884 £349,190.41 £2,005.05 £523,813.12 £3,003.10 
 One off exam £178.68 £26.50 17.479 0.097 -0.729 £349,394.32 £1,949.53 £524,180.82 £2,920.43 
 monitor every 5 years £431.40 £51.65 17.494 0.093 -0.240 £349,450.46 £1,853.72 £524,391.38 £2,778.69 
 monitor every 4 years £514.95 £61.20 17.497 0.092 -0.195 £349,426.13 £1,838.51 £524,396.68 £2,755.86 
 monitor every 3 years £673.11 £79.94 17.503 0.091 -0.045 £349,377.80 £1,829.93 £524,403.26 £2,743.19 
 monitor every 2 years £935.89 £111.88 17.506 0.091 0.234 £349,188.59 £1,815.52 £524,250.83 £2,721.70 
 Annual monitor £2,173.35 £264.45 17.510 0.091 1.024 £348,019.14 £1,825.64 £523,115.39 £2,728.08 
30 Do nothing £59.03 £23.23 17.455 0.101 -1.015 £349,031.58 £2,030.09 £523,576.89 £3,040.02 
 One off exam £182.58 £27.65 17.473 0.098 -0.842 £349,269.40 £1,972.09 £523,995.39 £2,953.70 
 monitor every 5 years £434.89 £52.07 17.489 0.093 -0.285 £349,349.03 £1,857.32 £524,241.00 £2,783.83 
 monitor every 4 years £518.31 £61.39 17.493 0.092 -0.225 £349,332.43 £1,844.28 £524,257.80 £2,764.35 
 monitor every 3 years £676.34 £80.10 17.499 0.091 -0.062 £349,306.95 £1,831.65 £524,298.59 £2,745.68 
 monitor every 2 years £938.96 £111.89 17.502 0.091 0.227 £349,105.86 £1,818.26 £524,128.27 £2,725.77 
 Annual monitor £2,176.54 £264.07 17.506 0.091 0.928 £347,941.95 £1,822.79 £523,001.20 £2,723.32 
31 Do nothing £76.34 £32.74 17.420 0.118 -5.418 £348,324.26 £2,379.76 £522,524.55 £3,559.71 
 One off exam £199.50 £36.57 17.443 0.113 -4.708 £348,666.25 £2,285.10 £523,099.12 £3,418.56 
 monitor every 5 years £450.01 £58.69 17.469 0.101 -2.297 £348,930.19 £2,022.57 £523,620.29 £3,027.74 
 monitor every 4 years £532.08 £66.80 17.474 0.098 -1.755 £348,951.41 £1,977.97 £523,693.16 £2,961.42 
 monitor every 3 years £687.79 £83.63 17.483 0.096 -1.048 £348,970.25 £1,927.63 £523,799.28 £2,886.96 
 monitor every 2 years £946.98 £113.19 17.489 0.094 -0.283 £348,824.31 £1,880.39 £523,709.95 £2,817.28 
 Annual monitor £2,171.55 £262.73 17.495 0.092 1.015 £347,723.41 £1,856.08 £522,670.90 £2,773.86 
32 Do nothing £93.64 £42.25 17.386 0.135 -9.821 £347,616.93 £2,729.42 £521,472.22 £4,079.41 
 One off exam £216.42 £45.48 17.414 0.129 -8.574 £348,063.10 £2,598.10 £522,202.86 £3,883.41 
 monitor every 5 years £465.14 £65.31 17.449 0.108 -4.308 £348,511.34 £2,187.83 £522,999.58 £3,271.64 
 monitor every 4 years £545.85 £72.22 17.456 0.105 -3.286 £348,570.40 £2,111.66 £523,128.52 £3,158.49 
 monitor every 3 years £699.25 £87.15 17.467 0.101 -2.035 £348,633.56 £2,023.62 £523,299.96 £3,028.25 
 monitor every 2 years £955.00 £114.50 17.475 0.097 -0.793 £348,542.76 £1,942.52 £523,291.64 £2,908.79 
 Annual monitor £2,166.56 £261.38 17.484 0.094 1.101 £347,504.87 £1,889.37 £522,340.59 £2,824.40 
33 Do nothing £110.95 £51.77 17.351 0.152 -14.224 £346,909.60 £3,079.09 £520,419.88 £4,599.11 
 One off exam £233.35 £54.40 17.385 0.144 -12.440 £347,459.94 £2,911.10 £521,306.59 £4,348.27 
 monitor every 5 years £480.26 £71.92 17.429 0.116 -6.320 £348,092.50 £2,353.08 £522,378.87 £3,515.55 
 monitor every 4 years £559.62 £77.64 17.437 0.111 -4.817 £348,189.38 £2,245.34 £522,563.88 £3,355.56 
 monitor every 3 years £710.70 £90.68 17.450 0.105 -3.022 £348,296.87 £2,119.60 £522,800.65 £3,169.54 
 monitor every 2 years £963.01 £115.80 17.461 0.100 -1.304 £348,261.21 £2,004.65 £522,873.32 £3,000.30 
 Annual monitor £2,161.57 £260.04 17.472 0.096 1.187 £347,286.33 £1,922.66 £522,010.28 £2,874.94 
34 Do nothing £128.26 £61.28 17.317 0.169 -18.627 £346,202.28 £3,428.76 £519,367.55 £5,118.81 
 One off exam £250.27 £63.31 17.355 0.159 -16.306 £346,856.79 £3,224.11 £520,410.32 £4,813.12 
 monitor every 5 years £495.38 £78.54 17.408 0.124 -8.331 £347,673.65 £2,518.34 £521,758.17 £3,759.46 
 monitor every 4 years £573.38 £83.06 17.419 0.117 -6.348 £347,808.37 £2,379.03 £521,999.25 £3,552.63 
 monitor every 3 years £722.16 £94.21 17.434 0.110 -4.008 £347,960.17 £2,215.59 £522,301.34 £3,310.83 
 monitor every 2 years £971.03 £117.11 17.448 0.103 -1.814 £347,979.66 £2,066.78 £522,455.01 £3,091.81 
 Annual monitor £2,156.58 £258.70 17.461 0.098 1.274 £347,067.79 £1,955.95 £521,679.98 £2,925.48 
44 
 
35 Do nothing £145.57 £70.79 17.282 0.186 -23.030 £345,494.95 £3,778.43 £518,315.21 £5,638.50 
 One off exam £267.19 £72.23 17.326 0.174 -20.172 £346,253.64 £3,537.11 £519,514.06 £5,277.97 
 monitor every 5 years £510.51 £85.16 17.388 0.132 -10.343 £347,254.80 £2,683.59 £521,137.46 £4,003.37 
 monitor every 4 years £587.15 £88.47 17.401 0.124 -7.878 £347,427.36 £2,512.72 £521,434.61 £3,749.70 
 monitor every 3 years £733.61 £97.74 17.418 0.114 -4.995 £347,623.48 £2,311.57 £521,802.03 £3,452.12 
 monitor every 2 years £979.05 £118.41 17.434 0.106 -2.324 £347,698.11 £2,128.91 £522,036.69 £3,183.32 
 Annual monitor £2,151.59 £257.35 17.450 0.099 1.360 £346,849.25 £1,989.24 £521,349.67 £2,976.02 
36 Do nothing £162.88 £80.30 17.248 0.203 -27.433 £344,787.62 £4,128.09 £517,262.88 £6,158.20 
 One off exam £284.11 £81.14 17.297 0.189 -24.038 £345,650.49 £3,850.12 £518,617.79 £5,742.83 
 monitor every 5 years £525.63 £91.78 17.368 0.140 -12.354 £346,835.96 £2,848.85 £520,516.75 £4,247.27 
 monitor every 4 years £600.92 £93.89 17.382 0.130 -9.409 £347,046.34 £2,646.41 £520,869.97 £3,946.77 
 monitor every 3 years £745.07 £101.26 17.402 0.119 -5.981 £347,286.79 £2,407.55 £521,302.72 £3,593.40 
 monitor every 2 years £987.07 £119.71 17.420 0.108 -2.835 £347,416.56 £2,191.04 £521,618.38 £3,274.83 
 Annual monitor £2,146.60 £256.01 17.439 0.101 1.446 £346,630.71 £2,022.53 £521,019.37 £3,026.56 
37 Do nothing £180.19 £89.81 17.213 0.220 -31.836 £344,080.30 £4,477.76 £516,210.54 £6,677.90 
 One off exam £301.03 £90.06 17.267 0.204 -27.904 £345,047.34 £4,163.12 £517,721.52 £6,207.68 
 monitor every 5 years £540.75 £98.40 17.348 0.148 -14.366 £346,417.11 £3,014.10 £519,896.04 £4,491.18 
 monitor every 4 years £614.69 £99.31 17.364 0.136 -10.940 £346,665.33 £2,780.09 £520,305.33 £4,143.84 
 monitor every 3 years £756.52 £104.79 17.385 0.123 -6.968 £346,950.10 £2,503.54 £520,803.41 £3,734.69 
 monitor every 2 years £995.09 £121.02 17.407 0.111 -3.345 £347,135.01 £2,253.17 £521,200.06 £3,366.34 
 Annual monitor £2,141.60 £254.67 17.428 0.103 1.533 £346,412.17 £2,055.82 £520,689.06 £3,077.10 
38 Do nothing £197.50 £99.32 17.179 0.237 -36.239 £343,372.97 £4,827.43 £515,158.21 £7,197.59 
 One off exam £317.95 £98.97 17.238 0.220 -31.770 £344,444.19 £4,476.12 £516,825.26 £6,672.53 
 monitor every 5 years £555.88 £105.02 17.328 0.156 -16.377 £345,998.27 £3,179.36 £519,275.34 £4,735.09 
 monitor every 4 years £628.46 £104.73 17.346 0.143 -12.471 £346,284.31 £2,913.78 £519,740.70 £4,340.91 
 monitor every 3 years £767.98 £108.32 17.369 0.128 -7.955 £346,613.40 £2,599.52 £520,304.10 £3,875.98 
 monitor every 2 years £1,003.11 £122.32 17.393 0.114 -3.855 £346,853.46 £2,315.30 £520,781.75 £3,457.85 
 Annual monitor £2,136.61 £253.32 17.417 0.104 1.619 £346,193.63 £2,089.10 £520,358.75 £3,127.64 
39 Do nothing £214.81 £108.83 17.144 0.254 -40.642 £342,665.64 £5,177.10 £514,105.87 £7,717.29 
 One off exam £334.87 £107.88 17.209 0.235 -35.636 £343,841.04 £4,789.13 £515,928.99 £7,137.39 
 monitor every 5 years £571.00 £111.64 17.308 0.163 -18.389 £345,579.42 £3,344.62 £518,654.63 £4,979.00 
 monitor every 4 years £642.22 £110.14 17.327 0.149 -14.001 £345,903.30 £3,047.47 £519,176.06 £4,537.98 
 monitor every 3 years £779.43 £111.84 17.353 0.132 -8.941 £346,276.71 £2,695.51 £519,804.78 £4,017.27 
 monitor every 2 years £1,011.13 £123.63 17.379 0.117 -4.365 £346,571.91 £2,377.43 £520,363.43 £3,549.36 
 Annual monitor £2,131.62 £251.98 17.405 0.106 1.706 £345,975.09 £2,122.39 £520,028.45 £3,178.17 
40 Do nothing £232.12 £118.34 17.110 0.271 -45.045 £341,958.32 £5,526.76 £513,053.54 £8,236.99 
 One off exam £351.80 £116.80 17.179 0.250 -39.502 £343,237.88 £5,102.13 £515,032.72 £7,602.24 
 monitor every 5 years £586.12 £118.26 17.287 0.171 -20.401 £345,160.57 £3,509.87 £518,033.92 £5,222.90 
 monitor every 4 years £655.99 £115.56 17.309 0.155 -15.532 £345,522.28 £3,181.15 £518,611.42 £4,735.05 
 monitor every 3 years £790.89 £115.37 17.337 0.137 -9.928 £345,940.02 £2,791.49 £519,305.47 £4,158.56 
 monitor every 2 years £1,019.15 £124.93 17.365 0.120 -4.876 £346,290.36 £2,439.56 £519,945.12 £3,640.87 
 Annual monitor £2,126.63 £250.64 17.394 0.108 1.792 £345,756.55 £2,155.68 £519,698.14 £3,228.71 
41 Do nothing £249.43 £127.85 17.075 0.288 -49.448 £341,250.99 £5,876.43 £512,001.20 £8,756.69 
 One off exam £368.72 £125.71 17.150 0.265 -43.368 £342,634.73 £5,415.14 £514,136.46 £8,067.10 
 monitor every 5 years £601.25 £124.87 17.267 0.179 -22.412 £344,741.73 £3,675.13 £517,413.22 £5,466.81 
 monitor every 4 years £669.76 £120.98 17.291 0.162 -17.063 £345,141.27 £3,314.84 £518,046.78 £4,932.12 
 monitor every 3 years £802.34 £118.90 17.320 0.141 -10.914 £345,603.33 £2,887.47 £518,806.16 £4,299.84 
 monitor every 2 years £1,027.17 £126.23 17.352 0.123 -5.386 £346,008.81 £2,501.69 £519,526.80 £3,732.38 
45 
 
 Annual monitor £2,121.64 £249.29 17.383 0.110 1.878 £345,538.01 £2,188.97 £519,367.83 £3,279.25 
42 Do nothing £266.74 £137.36 17.041 0.305 -53.851 £340,543.66 £6,226.10 £510,948.87 £9,276.38 
 One off exam £385.64 £134.63 17.121 0.280 -47.233 £342,031.58 £5,728.14 £513,240.19 £8,531.95 
 monitor every 5 years £616.37 £131.49 17.247 0.187 -24.424 £344,322.88 £3,840.38 £516,792.51 £5,710.72 
 monitor every 4 years £683.53 £126.40 17.272 0.168 -18.594 £344,760.26 £3,448.53 £517,482.15 £5,129.19 
 monitor every 3 years £813.80 £122.42 17.304 0.146 -11.901 £345,266.63 £2,983.46 £518,306.85 £4,441.13 
 monitor every 2 years £1,035.18 £127.54 17.338 0.126 -5.896 £345,727.26 £2,563.82 £519,108.49 £3,823.89 
 Annual monitor £2,116.65 £247.95 17.372 0.111 1.965 £345,319.47 £2,222.26 £519,037.53 £3,329.79 
43 Do nothing £284.05 £146.88 17.006 0.322 -58.253 £339,836.34 £6,575.77 £509,896.53 £9,796.08 
 One off exam £402.56 £143.54 17.092 0.296 -51.099 £341,428.43 £6,041.14 £512,343.93 £8,996.80 
 monitor every 5 years £631.50 £138.11 17.227 0.195 -26.435 £343,904.04 £4,005.64 £516,171.80 £5,954.63 
 monitor every 4 years £697.30 £131.81 17.254 0.174 -20.124 £344,379.24 £3,582.21 £516,917.51 £5,326.26 
 monitor every 3 years £825.25 £125.95 17.288 0.150 -12.888 £344,929.94 £3,079.44 £517,807.54 £4,582.42 
 monitor every 2 years £1,043.20 £128.84 17.324 0.129 -6.407 £345,445.71 £2,625.95 £518,690.17 £3,915.40 
 Annual monitor £2,111.66 £246.60 17.361 0.113 2.051 £345,100.93 £2,255.55 £518,707.22 £3,380.33 
44 Do nothing £301.35 £156.39 16.972 0.339 -62.656 £339,129.01 £6,925.43 £508,844.19 £10,315.78 
 One off exam £419.48 £152.46 17.062 0.311 -54.965 £340,825.28 £6,354.15 £511,447.66 £9,461.66 
 monitor every 5 years £646.62 £144.73 17.207 0.203 -28.447 £343,485.19 £4,170.89 £515,551.09 £6,198.54 
 monitor every 4 years £711.06 £137.23 17.235 0.181 -21.655 £343,998.23 £3,715.90 £516,352.87 £5,523.33 
 monitor every 3 years £836.71 £129.48 17.271 0.155 -13.874 £344,593.25 £3,175.43 £517,308.23 £4,723.71 
 monitor every 2 years £1,051.22 £130.15 17.311 0.132 -6.917 £345,164.16 £2,688.08 £518,271.86 £4,006.91 
 Annual monitor £2,106.67 £245.26 17.349 0.115 2.137 £344,882.39 £2,288.84 £518,376.92 £3,430.87 
45 Do nothing £318.66 £165.90 16.937 0.356 -67.059 £338,421.68 £7,275.10 £507,791.86 £10,835.48 
 One off exam £436.40 £161.37 17.033 0.326 -58.831 £340,222.13 £6,667.15 £510,551.39 £9,926.51 
 monitor every 5 years £661.74 £151.35 17.186 0.211 -30.458 £343,066.34 £4,336.15 £514,930.39 £6,442.44 
 monitor every 4 years £724.83 £142.65 17.217 0.187 -23.186 £343,617.21 £3,849.59 £515,788.24 £5,720.40 
 monitor every 3 years £848.17 £133.01 17.255 0.159 -14.861 £344,256.55 £3,271.41 £516,808.91 £4,865.00 
 monitor every 2 years £1,059.24 £131.45 17.297 0.135 -7.427 £344,882.61 £2,750.21 £517,853.54 £4,098.41 
 Annual monitor £2,101.68 £243.92 17.338 0.116 2.224 £344,663.85 £2,322.13 £518,046.61 £3,481.41 
46 Do nothing £335.97 £175.41 16.903 0.373 -71.462 £337,714.36 £7,624.77 £506,739.52 £11,355.17 
 One off exam £453.32 £170.29 17.004 0.341 -62.697 £339,618.98 £6,980.15 £509,655.13 £10,391.36 
 monitor every 5 years £676.87 £157.97 17.166 0.219 -32.470 £342,647.50 £4,501.40 £514,309.68 £6,686.35 
 monitor every 4 years £738.60 £148.07 17.199 0.193 -24.717 £343,236.20 £3,983.27 £515,223.60 £5,917.46 
 monitor every 3 years £859.62 £136.53 17.239 0.164 -15.848 £343,919.86 £3,367.39 £516,309.60 £5,006.28 
 monitor every 2 years £1,067.26 £132.76 17.283 0.138 -7.938 £344,601.06 £2,812.34 £517,435.23 £4,189.92 
 Annual monitor £2,096.69 £242.57 17.327 0.118 2.310 £344,445.31 £2,355.42 £517,716.30 £3,531.95 
47 Do nothing £353.28 £184.92 16.868 0.390 -75.865 £337,007.03 £7,974.44 £505,687.19 £11,874.87 
 One off exam £470.25 £179.20 16.974 0.356 -66.563 £339,015.82 £7,293.16 £508,758.86 £10,856.22 
 monitor every 5 years £691.99 £164.59 17.146 0.226 -34.481 £342,228.65 £4,666.66 £513,688.97 £6,930.26 
 monitor every 4 years £752.37 £153.48 17.180 0.200 -26.247 £342,855.18 £4,116.96 £514,658.96 £6,114.53 
 monitor every 3 years £871.08 £140.06 17.223 0.168 -16.834 £343,583.17 £3,463.38 £515,810.29 £5,147.57 
 monitor every 2 years £1,075.28 £134.06 17.270 0.141 -8.448 £344,319.51 £2,874.47 £517,016.91 £4,281.43 
 Annual monitor £2,091.70 £241.23 17.316 0.120 2.396 £344,226.77 £2,388.71 £517,386.00 £3,582.49 
48 Do nothing £370.59 £194.43 16.834 0.407 -80.268 £336,299.71 £8,324.10 £504,634.85 £12,394.57 
 One off exam £487.17 £188.12 16.945 0.371 -70.429 £338,412.67 £7,606.16 £507,862.59 £11,321.07 
 monitor every 5 years £707.11 £171.21 17.126 0.234 -36.493 £341,809.81 £4,831.92 £513,068.27 £7,174.17 
 monitor every 4 years £766.14 £158.90 17.162 0.206 -27.778 £342,474.17 £4,250.65 £514,094.32 £6,311.60 
 monitor every 3 years £882.53 £143.59 17.206 0.173 -17.821 £343,246.48 £3,559.36 £515,310.98 £5,288.86 
46 
 
 monitor every 2 years £1,083.30 £135.36 17.256 0.144 -8.958 £344,037.97 £2,936.60 £516,598.60 £4,372.94 
 Annual monitor £2,086.70 £239.89 17.305 0.122 2.483 £344,008.23 £2,421.99 £517,055.69 £3,633.03 
49 Do nothing £387.90 £203.94 16.799 0.424 -84.671 £335,592.38 £8,673.77 £503,582.52 £12,914.27 
 One off exam £504.09 £197.03 16.916 0.387 -74.295 £337,809.52 £7,919.17 £506,966.33 £11,785.92 
 monitor every 5 years £722.24 £177.82 17.106 0.242 -38.505 £341,390.96 £4,997.17 £512,447.56 £7,418.07 
 monitor every 4 years £779.90 £164.32 17.144 0.212 -29.309 £342,093.16 £4,384.34 £513,529.69 £6,508.67 
 monitor every 3 years £893.99 £147.11 17.190 0.178 -18.807 £342,909.78 £3,655.35 £514,811.67 £5,430.15 
 monitor every 2 years £1,091.32 £136.67 17.242 0.147 -9.468 £343,756.42 £2,998.73 £516,180.28 £4,464.45 
 Annual monitor £2,081.71 £238.54 17.294 0.123 2.569 £343,789.69 £2,455.28 £516,725.38 £3,683.57 
50 Do nothing £405.21 £213.45 16.765 0.441 -89.074 £334,885.05 £9,023.44 £502,530.18 £13,433.96 
 One off exam £521.01 £205.95 16.886 0.402 -78.161 £337,206.37 £8,232.17 £506,070.06 £12,250.78 
 monitor every 5 years £737.36 £184.44 17.085 0.250 -40.516 £340,972.11 £5,162.43 £511,826.85 £7,661.98 
 monitor every 4 years £793.67 £169.74 17.125 0.219 -30.840 £341,712.14 £4,518.02 £512,965.05 £6,705.74 
 monitor every 3 years £905.44 £150.64 17.174 0.182 -19.794 £342,573.09 £3,751.33 £514,312.36 £5,571.44 
 monitor every 2 years £1,099.34 £137.97 17.229 0.150 -9.979 £343,474.87 £3,060.86 £515,761.97 £4,555.96 
 Annual monitor £2,076.72 £237.20 17.282 0.125 2.655 £343,571.14 £2,488.57 £516,395.08 £3,734.11 
51 Do nothing £453.36 £234.11 16.638 0.502 -121.754 £332,302.97 £10,252.37 £498,681.14 £15,267.56 
 One off exam £567.16 £224.62 16.787 0.453 -104.366 £335,167.86 £9,265.32 £503,035.37 £13,791.51 
 monitor every 5 years £776.85 £199.26 17.021 0.276 -52.575 £339,643.01 £5,695.73 £509,852.94 £8,454.23 
 monitor every 4 years £828.33 £182.11 17.067 0.240 -39.667 £340,504.80 £4,963.06 £511,171.37 £7,366.68 
 monitor every 3 years £932.44 £159.41 17.122 0.199 -25.191 £341,515.20 £4,100.45 £512,739.02 £6,090.11 
 monitor every 2 years £1,115.75 £142.07 17.184 0.162 -12.514 £342,558.88 £3,323.06 £514,396.19 £4,946.31 
 Annual monitor £2,053.25 £237.34 17.244 0.135 3.392 £342,822.39 £2,687.12 £515,260.21 £4,033.51 
52 Do nothing £501.50 £254.77 16.511 0.562 -154.434 £329,720.89 £11,481.30 £494,832.09 £17,101.16 
 One off exam £613.31 £243.30 16.687 0.503 -130.571 £333,129.35 £10,298.47 £500,000.68 £15,332.25 
 monitor every 5 years £816.33 £214.08 16.957 0.302 -64.634 £338,313.90 £6,229.04 £507,879.02 £9,246.49 
 monitor every 4 years £862.99 £194.48 17.008 0.262 -48.494 £339,297.46 £5,408.10 £509,377.68 £8,027.61 
 monitor every 3 years £959.44 £168.17 17.071 0.216 -30.589 £340,457.31 £4,449.57 £511,165.68 £6,608.79 
 monitor every 2 years £1,132.16 £146.17 17.139 0.175 -15.049 £341,642.89 £3,585.26 £513,030.41 £5,336.67 
 Annual monitor £2,029.78 £237.48 17.205 0.145 4.128 £342,073.63 £2,885.67 £514,125.34 £4,332.92 
53 Do nothing £549.65 £275.42 16.384 0.622 -187.115 £327,138.82 £12,710.23 £490,983.05 £18,934.76 
 One off exam £659.47 £261.97 16.588 0.554 -156.775 £331,090.84 £11,331.61 £496,966.00 £16,872.98 
 monitor every 5 years £855.82 £228.90 16.892 0.328 -76.692 £336,984.80 £6,762.34 £505,905.11 £10,038.74 
 monitor every 4 years £897.66 £206.84 16.949 0.284 -57.321 £338,090.12 £5,853.14 £507,584.00 £8,688.55 
 monitor every 3 years £986.44 £176.94 17.019 0.233 -35.986 £339,399.41 £4,798.70 £509,592.34 £7,127.46 
 monitor every 2 years £1,148.58 £150.27 17.094 0.188 -17.585 £340,726.90 £3,847.45 £511,664.64 £5,727.02 
 Annual monitor £2,006.31 £237.61 17.167 0.155 4.864 £341,324.88 £3,084.22 £512,990.47 £4,632.32 
54 Do nothing £597.80 £296.08 16.258 0.683 -219.795 £324,556.74 £13,939.17 £487,134.00 £20,768.35 
 One off exam £705.62 £280.65 16.488 0.605 -182.980 £329,052.33 £12,364.76 £493,931.31 £18,413.71 
 monitor every 5 years £895.31 £243.72 16.828 0.354 -88.751 £335,655.70 £7,295.65 £503,931.20 £10,831.00 
 monitor every 4 years £932.32 £219.21 16.891 0.305 -66.148 £336,882.78 £6,298.18 £505,790.32 £9,349.48 
 monitor every 3 years £1,013.43 £185.70 16.968 0.250 -41.383 £338,341.52 £5,147.82 £508,019.00 £7,646.14 
 monitor every 2 years £1,164.99 £154.37 17.049 0.201 -20.120 £339,810.91 £4,109.65 £510,298.86 £6,117.37 
 Annual monitor £1,982.84 £237.75 17.128 0.165 5.601 £340,576.12 £3,282.77 £511,855.60 £4,931.73 
55 Do nothing £645.95 £316.74 16.131 0.743 -252.475 £321,974.66 £15,168.10 £483,284.96 £22,601.95 
 One off exam £751.77 £299.32 16.388 0.656 -209.185 £327,013.83 £13,397.91 £490,896.62 £19,954.45 
 monitor every 5 years £934.79 £258.54 16.763 0.379 -100.810 £334,326.59 £7,828.95 £501,957.28 £11,623.25 
 monitor every 4 years £966.98 £231.58 16.832 0.327 -74.975 £335,675.43 £6,743.21 £503,996.64 £10,010.42 
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 monitor every 3 years £1,040.43 £194.47 16.916 0.267 -46.780 £337,283.63 £5,496.94 £506,445.66 £8,164.81 
 monitor every 2 years £1,181.41 £158.47 17.004 0.214 -22.655 £338,894.92 £4,371.85 £508,933.08 £6,507.73 
 Annual monitor £1,959.37 £237.89 17.089 0.175 6.337 £339,827.37 £3,481.32 £510,720.74 £5,231.13 
56 Do nothing £694.09 £337.40 16.004 0.804 -285.155 £319,392.58 £16,397.03 £479,435.91 £24,435.55 
 One off exam £797.92 £318.00 16.289 0.706 -235.389 £324,975.32 £14,431.06 £487,861.94 £21,495.18 
 monitor every 5 years £974.28 £273.36 16.699 0.405 -112.869 £332,997.49 £8,362.26 £499,983.37 £12,415.51 
 monitor every 4 years £1,001.64 £243.95 16.773 0.348 -83.802 £334,468.09 £7,188.25 £502,202.96 £10,671.35 
 monitor every 3 years £1,067.43 £203.23 16.865 0.284 -52.178 £336,225.74 £5,846.06 £504,872.32 £8,683.49 
 monitor every 2 years £1,197.82 £162.57 16.959 0.226 -25.191 £337,978.93 £4,634.05 £507,567.31 £6,898.08 
 Annual monitor £1,935.89 £238.03 17.051 0.185 7.074 £339,078.61 £3,679.86 £509,585.87 £5,530.54 
57 Do nothing £742.24 £358.05 15.878 0.864 -317.836 £316,810.50 £17,625.96 £475,586.87 £26,269.14 
 One off exam £844.07 £336.67 16.189 0.757 -261.594 £322,936.81 £15,464.21 £484,827.25 £23,035.92 
 monitor every 5 years £1,013.77 £288.17 16.634 0.431 -124.928 £331,668.38 £8,895.56 £498,009.45 £13,207.76 
 monitor every 4 years £1,036.30 £256.32 16.715 0.370 -92.629 £333,260.75 £7,633.29 £500,409.28 £11,332.29 
 monitor every 3 years £1,094.43 £212.00 16.813 0.301 -57.575 £335,167.85 £6,195.18 £503,298.98 £9,202.16 
 monitor every 2 years £1,214.24 £166.67 16.914 0.239 -27.726 £337,062.94 £4,896.24 £506,201.53 £7,288.43 
 Annual monitor £1,912.42 £238.17 17.012 0.195 7.810 £338,329.86 £3,878.41 £508,451.00 £5,829.94 
58 Do nothing £790.39 £378.71 15.751 0.925 -350.516 £314,228.42 £18,854.89 £471,737.82 £28,102.74 
 One off exam £890.23 £355.35 16.089 0.808 -287.799 £320,898.30 £16,497.35 £481,792.56 £24,576.65 
 monitor every 5 years £1,053.25 £302.99 16.570 0.457 -136.986 £330,339.28 £9,428.87 £496,035.54 £14,000.01 
 monitor every 4 years £1,070.96 £268.69 16.656 0.392 -101.456 £332,053.41 £8,078.33 £498,615.60 £11,993.22 
 monitor every 3 years £1,121.43 £220.76 16.762 0.318 -62.972 £334,109.95 £6,544.30 £501,725.65 £9,720.84 
 monitor every 2 years £1,230.65 £170.77 16.869 0.252 -30.261 £336,146.95 £5,158.44 £504,835.75 £7,678.78 
 Annual monitor £1,888.95 £238.31 16.974 0.205 8.546 £337,581.10 £4,076.96 £507,316.13 £6,129.35 
59 Do nothing £838.54 £399.37 15.624 0.985 -383.196 £311,646.34 £20,083.83 £467,888.78 £29,936.34 
 One off exam £936.38 £374.03 15.990 0.859 -314.004 £318,859.79 £17,530.50 £478,757.87 £26,117.38 
 monitor every 5 years £1,092.74 £317.81 16.505 0.483 -149.045 £329,010.17 £9,962.17 £494,061.63 £14,792.27 
 monitor every 4 years £1,105.62 £281.06 16.598 0.413 -110.283 £330,846.07 £8,523.37 £496,821.91 £12,654.16 
 monitor every 3 years £1,148.43 £229.52 16.710 0.335 -68.370 £333,052.06 £6,893.43 £500,152.31 £10,239.51 
 monitor every 2 years £1,247.06 £174.87 16.824 0.265 -32.797 £335,230.96 £5,420.64 £503,469.98 £8,069.14 
 Annual monitor £1,865.48 £238.44 16.935 0.216 9.283 £336,832.35 £4,275.51 £506,181.26 £6,428.75 
60 Do nothing £886.68 £420.03 15.498 1.046 -415.876 £309,064.26 £21,312.76 £464,039.74 £31,769.94 
 One off exam £982.53 £392.70 15.890 0.909 -340.208 £316,821.28 £18,563.65 £475,723.19 £27,658.12 
 monitor every 5 years £1,132.23 £332.63 16.441 0.509 -161.104 £327,681.07 £10,495.48 £492,087.71 £15,584.52 
 monitor every 4 years £1,140.28 £293.43 16.539 0.435 -119.110 £329,638.73 £8,968.41 £495,028.23 £13,315.09 
 monitor every 3 years £1,175.43 £238.29 16.658 0.352 -73.767 £331,994.17 £7,242.55 £498,578.97 £10,758.19 
 monitor every 2 years £1,263.48 £178.97 16.779 0.278 -35.332 £334,314.97 £5,682.84 £502,104.20 £8,459.49 
 Annual monitor £1,842.01 £238.58 16.896 0.226 10.019 £336,083.59 £4,474.06 £505,046.39 £6,728.16 
 
  
48 
 
Appendix 11: Additional Figures 
Below are additional figures illustrating the results.  Figures A11.1a and A11.1b show the expected net 
benefit of each of the seven policies as a function of risk score.  At low risk scores there is very little 
difference between the policies.  However, at scores above 30, the net benefit of the less intensive 
policies drops dramatically: this is due to failure to detect melanomas, thus patients suffer reduced 
life expectancy, and the NHS suffers increased costs from treatment of late stage disease.   
Figure A11.2 shows the incremental net benefit +/- 95% credibility interval of the optimal risk-
stratified policy (as described in the results and Table 1), compared with the status quo, as a function 
of willingness to pay for a QALY. 
Figures A11.1a & A11.1b: Expected net benefit for each strategy as a function of risk score at (a) 
£20,000 and (b) £30,000 per QALY gained  
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Figure A11.2: Incremental Net Benefit +/- 95% Credibility Interval for compound risk-stratified 
policy vs status quo. 
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